<SEC-DOCUMENT>0001144204-16-107321.txt : 20160607
<SEC-HEADER>0001144204-16-107321.hdr.sgml : 20160607
<ACCEPTANCE-DATETIME>20160607170358
ACCESSION NUMBER:		0001144204-16-107321
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20160607
DATE AS OF CHANGE:		20160607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRANSGENOMIC INC
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-201907
		FILM NUMBER:		161701952

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>v441903_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 297.35pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 297.35pt; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Registration No. 333-201907</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(To Prospectus dated February 13, 2015) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>$3,500,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="tlogo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>TRANSGENOMIC,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Transgenomic, Inc. has
entered into an At the Market Offering Agreement, or the Sales Agreement, with Craig-Hallum Capital Group LLC, or Craig-Hallum,
relating to shares of our common stock that may be offered by this prospectus supplement and the accompanying prospectus. In accordance
with the terms of the Sales Agreement, we may offer and sell an aggregate of up to $3,500,000 of common stock from time to time
through Craig-Hallum, as sales manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Craig-Hallum is not required
to sell any specific number or dollar amount of shares of our common stock but will use its commercially reasonable efforts, as
our agent and subject to the terms of the Sales Agreement, to sell the shares offered by this prospectus supplement and the accompanying
prospectus. Sales of the shares, if any, will be made in an &ldquo;at the market&rdquo; offering as defined in Rule&nbsp;415 of
the Securities Act of 1933, as amended, or the Securities Act. Specifically, sales in this offering will be made directly on the
Nasdaq Capital Market, the existing trading market for our common stock, or on any other existing trading market for our common
stock, at market prices prevailing at the time of sale. In the event any sales are made pursuant to the Sales Agreement which are
not made directly on the Nasdaq Capital Market or on any other existing trading market for our common stock at market prices at
the time of sale, including, without limitation, any sales to the sales agent acting as principal or sales in privately negotiated
transactions, we will file a prospectus supplement describing the terms of such transaction, the amount of shares sold, the price
thereof, the applicable compensation, and such other information as may be required pursuant to Rule 424 and Rule 430B of the Securities
Act, as applicable, within the time required by Rule 424 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Craig-Hallum will receive from us a commission
of 3.25% based on the gross sales price per share for any shares sold through it as agent under the Sales Agreement. We have also
agreed to reimburse certain expenses of Craig-Hallum in connection with the Sales Agreement. The net proceeds to us that we receive
from sales of our common stock will depend on the number of shares actually sold and the offering price for such shares. The actual
proceeds to us will vary, but will not exceed $3,500,000 in the aggregate. See &ldquo;Plan of Distribution&rdquo; beginning on
page S-15&nbsp;of this prospectus supplement. In connection with the sale of shares of our common stock on our behalf, Craig-Hallum
may be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the compensation of Craig-Hallum
may be deemed to be underwriting commissions or discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our common stock is listed on Nasdaq Capital
Market under the symbol &ldquo;TBIO.&rdquo; On June 6, 2016, the last sale price of our shares of common stock as reported on the
Nasdaq Capital Market was $0.60 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of June 6, 2016, the aggregate market
value of our outstanding common stock held by non-affiliates was $11.2 million based on 22,846,408 shares of outstanding
common stock, of which 15,288,240 shares are held by non-affiliates, and a per share price of $0.73, based on the closing bid
price of our common stock as quoted on the Nasdaq Capital Market on April 20, 2016. We have not offered or sold any securities
pursuant to General Instruction I.B.6. of Form S-3 during the 12 calendar months prior to and including the date of this
prospectus supplement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><B>Investing in our
common stock involves risks, including those described in the &ldquo;Risk Factors&rdquo; section beginning on page  S-5 of
this prospectus supplement, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are incorporated herein by reference.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined that this prospectus supplement
or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; font-size: 10pt; text-align: center"><font style="font-size: 18pt"><b>Craig-Hallum Capital Group</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The date of this prospectus supplement is
June 7, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 95%; text-align: right">&nbsp;</td>
    <TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><b>Page</b></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001">About This Prospectus Supplement</A></td>
    <TD STYLE="text-align: right">S-1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_002">Prospectus Supplement Summary</A></td>
    <TD STYLE="text-align: right">S-2</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003">The Offering</A></td>
    <TD STYLE="text-align: right">S-4</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_004">Risk Factors</A></td>
    <TD STYLE="text-align: right">S-5</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005">Disclosure Regarding Forward-Looking Statements</A></td>
    <TD STYLE="text-align: right">S-13</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_006">Use of Proceeds</A></td>
    <TD STYLE="text-align: right">S-13</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007">Dilution</A></td>
    <TD STYLE="text-align: right">S-14</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_008">Plan of Distribution</A></td>
    <TD STYLE="text-align: right">S-15</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009">Legal Matters</A></td>
    <TD STYLE="text-align: right">S-16</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_010">Experts</A></td>
    <TD STYLE="text-align: right">S-16</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011">Where You Can Find More Information</A></td>
    <TD STYLE="text-align: right">S-16</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_012">Information Incorporated by Reference</A></td>
    <TD STYLE="text-align: right">S-17</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><b>Prospectus</b></td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_001">About This Prospectus</A></td>
    <TD STYLE="text-align: right">1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_002">Prospectus Summary</A></td>
    <TD STYLE="text-align: right">1</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_003">Risk Factors</A></td>
    <TD STYLE="text-align: right">2</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_004">Disclosure Regarding Forward-Looking Statements</A></td>
    <TD STYLE="text-align: right">3</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_005">Use of Proceeds</A></td>
    <TD STYLE="text-align: right">3</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_006">Ratio of Earnings to Fixed Charges and Preferred Share Dividends</A></td>
    <TD STYLE="text-align: right">4</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_007">Description of Capital Stock</A></td>
    <TD STYLE="text-align: right">4</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_008">Description of Debt Securities</A></td>
    <TD STYLE="text-align: right">8</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_009">Description of Warrants</A></td>
    <TD STYLE="text-align: right">15</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_010">Description of Units</A></td>
    <TD STYLE="text-align: right">17</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_011">Legal Ownership of Securities</A></td>
    <TD STYLE="text-align: right">17</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_012">Plan of Distribution</A></td>
    <TD STYLE="text-align: right">20</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_013">Legal Matters</A></td>
    <TD STYLE="text-align: right">22</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_014">Experts</A></td>
    <TD STYLE="text-align: right">22</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_015">Where You Can Find More Information</A></td>
    <TD STYLE="text-align: right">22</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_016">Important Information Incorporated by Reference</A></td>
    <TD STYLE="text-align: right">22</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_001"></A><B>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus supplement and the accompanying
prospectus are part of a registration statement that we filed with the Securities Exchange Commission, or the SEC, utilizing a
&ldquo;shelf&rdquo; registration process. This document is in two parts. The first part is the prospectus supplement, including
the documents incorporated by reference, which relates only to an offering of common stock having an aggregate offering price of
up to $3,500,000 through Craig-Hallum. These sales, if any, will be made pursuant to the terms of the Sales Agreement entered into
between us and Craig-Hallum on June 7, 2016, a copy of which has been filed with the SEC as an exhibit to a Current Report on Form
8-K and which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The second part, the accompanying prospectus,
including the documents incorporated by reference, provides more general information. Generally, when we refer to this prospectus,
we are referring to both parts of this document combined. Before you invest, you should carefully read this prospectus supplement,
the accompanying prospectus, all information incorporated by reference herein and therein, as well as the additional information
described under &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Information Incorporated by Reference&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These documents contain information you should
consider when making your investment decision. This prospectus supplement may add, update or change information contained in the
accompanying prospectus. To the extent that any statement that we make in this prospectus supplement is inconsistent with statements
made in the accompanying prospectus or any documents incorporated by reference, the statements made in this prospectus supplement
will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should rely only on the information contained
or incorporated by reference in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference
therein and any free writing prospectus we provide you. We have not, and Craig-Hallum has not, authorized anyone to provide you
with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are
not, and Craig-Hallum is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated
by reference in this prospectus supplement and the accompanying prospectus and any free writing prospectus we provide you is accurate
only as of the date on those respective documents. Our business, financial condition, results of operations and prospects may have
changed since those dates. You should read this prospectus supplement and the accompanying prospectus, including the documents
incorporated by reference in this prospectus supplement and the accompanying prospectus, when making your investment decision.
You should also read and consider the information in the documents we have referred you to in the sections of this prospectus supplement
entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Information Incorporated by Reference.&rdquo; The distribution
of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside
the United States, or the U.S., who come into possession of this prospectus supplement must inform themselves about, and observe
any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement outside the U.S.
This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of
an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful
for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, information contained
in this prospectus supplement, the accompanying prospectus or the documents incorporated by reference, concerning our industry
and the markets in which we operate, including our general expectations and market position, market opportunity and market share,
is based on information from our own management estimates and research, as well as from industry and general publications and research,
surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge
of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition, assumptions
and estimates of our and our industry&rsquo;s future performance are necessarily subject to a high degree of uncertainty and risk
due to a variety of factors, including those described in &ldquo;Risk Factors&rdquo; in this prospectus supplement, the accompanying
prospectus, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2016, which are incorporated by reference into this prospectus supplement. These and other important
factors could cause our future performance to differ materially from our assumptions and estimates. See &ldquo;Disclosure Regarding
Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">General information about us can be found on
our website at <U>www.transgenomic.com</U>. The information on our website is for informational purposes only and should not be
relied on for investment purposes. The information on our website is not incorporated by reference into either this prospectus
supplement or the accompanying prospectus and should not be considered part of this or any other report filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>This summary highlights selected information
contained elsewhere or incorporated by reference in this prospectus supplement. This summary does not contain all the information
that you should consider before investing in our common stock. Before making an investment decision, to fully understand this offering
and its consequences to you, you should carefully read this entire prospectus supplement and the accompanying prospectus, including
the &ldquo;Risk Factors&rdquo; of this prospectus supplement, the financial statements and related notes, and the other information
that we incorporate by reference into this prospectus supplement, including the section &ldquo;Risk Factors&rdquo; in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2015 and in our Quarterly Report on Form 10-Q for the quarter ended
March 31, 2016.<FONT STYLE="font-size: 10pt"> </FONT>This prospectus supplement contains forward-looking statements that involve
risks and uncertainties. Our actual results could differ materially from the results anticipated in these forward- looking statements
as a result of factors described under the &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus supplement. Unless
the context otherwise requires, any reference to &ldquo;Transgenomic,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo;
and &ldquo;us&rdquo; in this prospectus supplement refers to Transgenomic, Inc. and its subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Transgenomic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a biotechnology company advancing personalized
medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical
and research services. A key goal is to bring our Multiplexed ICE COLD-PCR, or MX-ICP, product to the clinical market through strategic
partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly
diagnosis, monitoring and treatment of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">MX-ICP is technology proprietary to Transgenomic.
It is a reagent that improves the ability to detect genetic mutations by 100 - 400 fold over existing technologies. This technology
has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital
PCR. By enhancing the level of detection of genetic mutations and suppressing the normal, or wild-type DNA, several benefits are
provided. It is generally understood that most current technologies are unable to consistently identify mutations that occur in
less than approximately 5% of a sample. However, many mutations found at much lower levels, even as low as 0.01%, are known to
be clinically relevant and can have significant consequences to a patient: both in terms of how they will respond to a given drug
or treatment and how a given tumor is likely to change over time. More importantly, in our view, is the ability to significantly
improve the level of detection while using blood, saliva and even urine as a source for DNA, rather than depending on painful,
expensive and potentially dangerous tumor biopsies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that this is an important advancement
in patient care with respect to cancer detection, treatment and monitoring and can result in significant cost savings for the healthcare
system by replacing invasive procedures with the simple collection of blood or other bodily fluids. By broadening the types of
samples that can be used for testing and allowing all sequencing platforms to provide improved identification of low level mutations,
MX-ICP has the potential to make testing more readily available, more patient friendly, enable genetic monitoring of disease progression,
effectively guide treatment protocols, and reduce the overall cost of diagnosis and monitoring while significantly improving patient
outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Historically, our operations were organized
and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic
Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment,
our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services
segment as discontinued operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our laboratory in Omaha, Nebraska is focused
on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase
III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing
service technologies, including our proprietary MX-ICP technology. ICE COLD-PCR is a proprietary ultra-high sensitivity platform
technology with breakthrough potential to enable wide adoption of personalized, precision medicine in cancer and other diseases.
It can be run in any laboratory that contains standard PCR systems. MX-ICP enables detection of multiple known and unknown mutations
from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA and circulating tumor cells at levels
greater than 1,000-fold higher than standard DNA sequencing techniques. It is easy to implement and use within existing workflows.
Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments, or CLIA, as a high complexity laboratory
and is accredited by the College of American Pathologists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are subject to a number of claims of various
amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded
accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25,
2016, the Board of Regents of the University of Nebraska, or UNMC, filed a lawsuit against us in the District Court of Douglas
County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in
discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has
been recorded and is reflected in accrued expenses at December 31, 2015 and March 31, 2016. In addition, on April 13, 2016, Fox
Chase Cancer Center, or Fox Chase, filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial
District of Pennsylvania Civil Trial Division alleging, among other things, breach of contract, tortious interference with present
and prospective contractual relations, unjust enrichment and fraudulent conversion, conspiracy and seeking punitive damages in
addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000,
as amended, or the License Agreement, as well as the assignment of certain of our rights under the License Agreement to Integrated
DNA Technologies, Inc., or IDT, pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into
with IDT effective as of July 1, 2014, or the IDT Agreement. Pursuant to the terms of the IDT Agreement, we agreed to indemnify
IDT with respect to certain of the claims asserted in the Fox Chase proceeding. We believe that we have good and substantial defenses
to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential
loss, and there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The outcome of legal proceedings and claims
brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome
to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess
of management&rsquo;s expectations, our financial statements for such reporting period could be materially adversely affected.
In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material
to our financial condition or cash flows, or both, or could otherwise adversely our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We were incorporated in Delaware on March 6,
1997. Our principal office is located at 12325 Emmet Street, Omaha, Nebraska 68164 and our telephone number is 402-452-5400. Our
website address is <U>www.transgenomic.com</U>. Information on our website, or that can be accessed through our website, is not
incorporated by reference into this prospectus and does not constitute part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For a complete description of our business,
financial condition, results of operations and other important information, we refer you to our filings with the SEC, that are
incorporated by reference in this prospectus, including our Annual Report on Form 10-K for the year ended December 31, 2015 and
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. For instructions on how to find copies of these documents,
see &ldquo;Where You Can Find More Information&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following is a brief summary of the terms
of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 30%; padding-top: 0pt; padding-bottom: 0pt">Issuer</td>
    <TD STYLE="width: 2%; text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="width: 68%; text-align: justify; padding-top: 0pt; padding-bottom: 0pt">Transgenomic, Inc.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt">Common stock to be offered by us pursuant to this prospectus supplement</td>
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-align: justify">&nbsp;</td>
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-align: justify">Up to $3,500,000 of common stock.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-align: justify">&nbsp;</td>
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt">Common stock to be outstanding after the offering</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: left; padding-top: 0pt; padding-bottom: 0pt">Up to 28,679,741 shares, assuming sales of all shares hereunder at a price of $0.60 per share, which was the closing price on the Nasdaq Capital Market on June 6, 2016.&nbsp;&nbsp;Actual shares issued will vary depending on the sales prices under this offering</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt">Manner of offering</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: left; padding-top: 0pt; padding-bottom: 0pt">Sales of shares of our common stock, if any, will be made pursuant to the terms of the Sales Agreement entered into between us and Craig-Hallum on June 7, 2016. Sales of the shares, if any, will be made in an &ldquo;at the market offering&rdquo;, as defined in Rule 415 under the Securities Act.&nbsp;&nbsp;Specifically, sales will be made directly on the Nasdaq Capital Market, the existing trading market for our common stock, or on any other existing trading market for our common stock, at market prices prevailing at the time of sale. Craig-Hallum will make these sales using commercially reasonable efforts consistent with its normal trading and sales practices and applicable law, on mutually agreeable terms between Craig-Hallum and us. The net proceeds to us that we receive from sales of our common stock will depend on the number of shares actually sold and the offering price for such shares. The actual proceeds to us will vary.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-indent: -0.25in; padding-left: 0.25in">Use of proceeds</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: left; padding-top: 0pt; padding-bottom: 0pt">We intend to apply the net proceeds of this offering to working capital and general corporate purposes, which may include, without limitation, supporting asset growth and engaging in acquisitions or other business combinations. We also may use a portion of the proceeds to repay debt. We reserve the right, at the sole discretion of our Board of Directors, to reallocate the proceeds of this offering in response to developments in our business and other factors. &nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-indent: -0.2in">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-indent: -0.25in; padding-left: 0.25in">Nasdaq symbol for common stock</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: left; padding-top: 0pt; padding-bottom: 0pt">Our common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;TBIO.&rdquo; </td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-indent: -0.2in">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; text-indent: -0.25in; padding-left: 0.25in">Risk factors</td>
    <TD STYLE="text-align: justify; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</td>
    <TD STYLE="text-align: left; padding-top: 0pt; padding-bottom: 0pt">See &ldquo;Risk Factors&rdquo; and other information included in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">Except as otherwise indicated, the information
contained in this prospectus supplement assumes the sale of all of the shares offered hereby assuming sales of all shares hereunder
at a price of $0.60 per share, which was the closing price on the Nasdaq Capital Market on June 6, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The number of shares of common stock to be outstanding
after this offering is based on 22,846,408 shares of common stock outstanding as of May 31, 2016 and does not take into account,
as of May 31, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,120,328 shares of our common stock issuable upon exercise of outstanding stock options to purchase shares of our common stock at a weighted average exercise price of $3.42 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,333 shares of our common stock issuable upon exercise of outstanding stock appreciation rights with a weighted average exercise price of $4.14 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">372,741 shares of our common stock reserved for issuance under our 2006 Equity Incentive Plan, as amended;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">241,705 shares of our Series A-1 Convertible Preferred Stock, which are convertible into shares of our common stock at a rate of 1-for-1, subject to certain adjustments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,853,905 shares of our common stock issuable in connection with our outstanding warrants with a weighted average exercise price of $3.10 per share; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon conversion of our unsecured outstanding convertible promissory notes in the aggregate principal amount of $571,250.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Investing in any securities offered pursuant
to this prospectus and the applicable prospectus supplement involves a high degree of risk. Before making an investment decision,
you should carefully consider the risks described under &ldquo;Risk Factors&rdquo; in any applicable prospectus supplement and
in our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on April 14, 2016, and our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2016<B> </B>filed with the SEC on May 23, 2016, together with all of the other
information appearing in or incorporated by reference into this prospectus supplement, before deciding whether to purchase any
of the securities being offered. Our business, financial condition or results of operations could be materially adversely affected
by any of these risks. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered
securities.<B> </B>Additional risks not presently known to us or that we currently believe are immaterial may also significantly
impair our business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have a history of operating losses and may incur losses in
the future.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have experienced annual losses from continuing operations since inception of our operations. Our operating loss for the years ended&nbsp;December&nbsp;31,
2015&nbsp;and&nbsp;2014&nbsp;was&nbsp;$9.2 million&nbsp;and&nbsp;$10.6 million, respectively, and for the three months ended March
31, 2016 and 2015 was&nbsp;$2.2</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">million&nbsp;and&nbsp;$2.0</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">million, respectively. These historical losses have been due principally
to the expenses that we have incurred in order to develop and market our products, the fixed nature of our manufacturing costs
and merger and acquisition costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Recurring operating losses raise substantial doubt about our
ability to continue as a going concern.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have incurred substantial operating losses and have used cash in our operating activities for the past several years. As of March
31, 2016, we had negative working capital of approximately $15.2</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">million.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">The audit
report issued by our independent registered public accounting firm for our financial statements for the fiscal year ended December&nbsp;31,
2015 states that our independent registered public accounting firm has substantial doubt in our ability to continue as a going
concern due to the risk that we may not have sufficient cash and liquid assets at December&nbsp;31, 2015 to cover our operating
and capital requirements for the next 12 months. If that is the case, and if sufficient cash cannot be obtained, we would have
to substantially alter, or possibly even discontinue, operations. Additionally, as of March 31, 2016, we do not believe that we
will have sufficient cash to meet our operating requirements for at least the next 12 months. Our financial statements and related
notes thereto incorporated by reference in this prospectus supplement do not include any adjustments that might result from the
outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our current operating plan projects improved
operating results, improvement in collection rates and monetization of underutilized assets. There are no guarantees that these
efforts will be successful and, if not, we may use more cash than projected and not be able to meet our current obligations. As
with any operating plan, there are risks associated with our ability to execute it. Therefore, there can be no assurance that we
will be able to satisfy our obligations, or achieve the operating improvements as contemplated by the current operating plan. If
we are unable to execute this plan, we will need to find additional sources of cash not contemplated by the current operating plan
and/or raise additional capital to sustain continuing operations as currently contemplated. We could seek to raise additional funds
through various potential sources such as through the sale of assets or sale of debt or equity securities. However, there can be
no assurance that the additional funding sources will be available to us at reasonable terms or at all. If we are unable to achieve
our operating plan or obtain additional financing, our business would be jeopardized and we may not be able to continue as a going
concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have substantial debt and other financial obligations and
we may incur even more debt, and, as of March 31, 2016, we were not in compliance with certain financial covenants contained in
our loan agreement with&nbsp;affiliates of Third Security, LLC. If we default under the loan agreement, the lenders will have the
right to cease</B> <B>making additional advances, accelerate repayment of all sums due and take action to collect the amounts owed
to them, including foreclosing on their security interest, each of which could adversely affect us.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
revolving line of credit and term loan with affiliates of Third Security, LLC, a related party, or the Lenders, are governed by
a Loan and Security Agreement, as amended, or the Loan and Security Agreement, which contains certain affirmative and negative
covenants. </FONT>As of March 31, 2016, we had borrowings of $6.8 million under the Loan and Security Agreement. <FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the term loan, we agreed not to, among other things, (i) pledge or otherwise encumber our assets other than to the Lenders, (ii)
enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions
without the Lenders&rsquo; consent. To secure the repayment of amounts borrowed under the revolving line of <FONT STYLE="background-color: white">credit</FONT>
and term loan, we granted the Lenders a security interest in all of our assets. As of March 31, 2016, we were not in compliance
with the financial covenants and certain other obligations applicable to us under the Loan and Security Agreement and had an outstanding
overadvance in the amount of $0.5 million and, therefore, we were in default under the Loan and Security Agreement. Effective June
6, 2016, we entered into an amendment to the Loan and Security Agreement with the Lenders. </FONT>The amendment, among other things,
(i) provides that the Lenders will waive the specified events of default under the terms of the Loan and Security Agreement, (ii)
amends the prepayment terms of the Loan and Security Agreement, (iii) provides for the reduction of amounts available under the
revolving line of credit upon the prepayment or repayment of certain amounts by us, (iv) removes the minimum liquidity ratio and
minimum net revenue financial covenants that were previously applicable to us under the Loan and Security Agreement, (v) amends
the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent
of the Lenders, and (vi) capitalizes certain amounts owed by us to the Lenders and adds such overdue amounts to the outstanding
principal amount of the revolving line of credit. However, there can be no assurance that we will not default under the Loan and
Security Agreement in the future or that, if we do, the Lenders will waive any or all of the events of default. If we are unable
to maintain compliance with the terms of the Loan and Security Agreement, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Lenders will have the right, among other things, to cease making additional advances, accelerate repayment of all sums due and
take action to collect the amounts owed to them, including foreclosing on their security interest or forcing us into bankruptcy,
which would have a material adverse effect on our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may be required to amend our Loan and Security
Agreement, refinance all or part of our existing debt, sell assets, incur additional indebtedness or raise equity. Our ability
to make scheduled payments on our debt and other financial obligations depends on our financial and operating performance. Our
financial and operating performance will continue to be subject to prevailing economic conditions and to financial, business and
other factors, some of which are beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our existing indebtedness could adversely affect our ability
to fulfill our obligations and may place us at a competitive disadvantage in our industry.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We continue to have substantial debt outstanding
and we may incur additional indebtedness from time to time to finance working capital, product development efforts, strategic acquisitions,
investments and alliances, capital expenditures or other general corporate purposes, subject to the restrictions contained in our
existing indebtedness and in any other agreements under which we incur indebtedness. Our outstanding indebtedness and debt service
requirements could adversely affect our ability to operate our business and may limit our ability to take advantage of potential
business opportunities. For example, our existing level of indebtedness presents the following risks:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we will be required to use a substantial portion of our cash flow from operations to pay principal and interest on our indebtedness,
thereby reducing the availability of our cash flow to fund working capital, capital expenditures, product development efforts,
acquisitions, investments and strategic alliances and other general corporate requirements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our debt service obligations could limit our flexibility in planning for, or reacting to, changes in our business and our industry
and could limit our ability to pursue other business opportunities, borrow more money for operations or capital in the future and
implement our business strategies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our level of indebtedness and the covenants within our debt instruments may restrict us from raising additional financing on
satisfactory terms to fund working capital, capital expenditures, product development efforts, strategic acquisitions, investments
and alliances, and other general corporate requirements; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our outstanding indebtedness may make it difficult for us to attract additional financing when needed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we are at any time unable to generate sufficient
cash flow from operations to service our indebtedness when payment is due, we may be required to attempt to renegotiate the terms
of the instruments relating to the indebtedness, seek to refinance all or a portion of the indebtedness or obtain additional financing.
There can be no assurance that we will be able to successfully renegotiate such terms, that any such refinancing would be possible
or that any additional financing could be obtained on terms that are favorable or acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our future capital needs are uncertain and we may need to raise
additional funds in the future.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
future </FONT>capital<FONT STYLE="font-family: Times New Roman, Times, Serif"> needs are uncertain and we may need to raise additional
funds in the future through debt or equity offerings. Our future capital requirements will depend on many factors, including, but
not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue generated by sales of our products</FONT>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Expenses incurred in manufacturing and selling our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Costs of developing new products or technologies</FONT>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Costs associated with capital expenditures</FONT>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The number and timing of strategic transactions; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Working capital requirements related to growing existing business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even if we sell the full $3,500,000 of common
stock pursuant to the Sales Agreement as contemplated in this prospectus supplement, we will likely need to raise additional funds
<FONT STYLE="font-family: Times New Roman, Times, Serif">through debt or equity offerings</FONT> in order to satisfy our capital
needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may need additional capital to finance our growth or to compete,
which may cause dilution to existing stockholders or limit our flexibility in conducting our business activities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may need to raise additional capital in the
future to fund expansion, respond to competitive pressures or acquire complementary businesses, technologies or services. Such
additional financing may not be available on terms acceptable to us or at all. To the extent that we raise additional capital by
issuing equity securities, our stockholders may experience substantial dilution, and to the extent we engage in additional debt
financing, if available, we may become subject to additional restrictive covenants that could limit our flexibility in conducting
future business activities. If additional financing is not available or not available on acceptable terms, we may not be able to
continue as a going concern, fund our expansion, promote our brands, take advantage of acquisition opportunities, develop or enhance
services or respond to competitive pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Governmental payers and health care plans have taken steps to
control costs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Medicare, Medicaid and private insurers have
increased their efforts to control the costs of health care services, including clinical testing services. They may reduce fee
schedules or limit/exclude coverage for certain types of tests that we perform. Medicaid reimbursement varies by state and is subject
to administrative and billing requirements and budget pressures. We expect efforts to reduce reimbursements, impose more stringent
cost controls and reduce utilization of testing services will continue. These efforts, including changes in laws or regulations,
may have a material adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Weakness in U.S. or global economic conditions could have an
adverse effect on our businesses.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The economies of the United States and other
regions of the world in which we do business have experienced significant weakness, which, in the case of the U.S., has recently
resulted in significant unemployment and slower growth in economic activity. A decline in economic conditions may adversely affect
demand for our services and products, thus reducing our revenue. These conditions could also impair the ability of those with whom
we do business to satisfy their obligations to us. The strengthening dollar has the potential to adversely impact U.S. businesses
that operate overseas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Sales have been variable.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our laboratory performs project-based work that
changes from quarter to quarter. Therefore, comparison of the results of successive quarters may not accurately reflect trends
or results for the full year due to the fact that ICP is a new product and will enable the liquid biopsy market to evolve rapidly
and ensure Precision Medicine is adopted globally. We see the ICP business and revenues growing as our commercial strategy is successful
and our partnerships and licensing agreements become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Changes in payer mix could have a material adverse impact on
our net sales and profitability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Testing services are billed to physicians, patients,
government payers such as Medicare, and insurance companies. Tests may be billed to different payers depending on a particular
patient&rsquo;s medical insurance coverage. Government payers have increased their efforts to control the cost, utilization and
delivery of health care services as well as reimbursement for laboratory testing services. Further reductions of reimbursement
for Medicare and Medicaid services or changes in policy regarding coverage of tests or other requirements for payment, such as
prior authorization or a physician or qualified practitioner&rsquo;s signature on test requisitions, may be implemented from time
to time. Reimbursement for the laboratory services component of our business is also subject to statutory and regulatory reduction.
Reductions in the reimbursement rates and changes in payment policies of other third party payers may occur as well. Such changes
in the past have resulted in reduced payments as well as added costs and have decreased test utilization for the clinical laboratory
industry by adding more complex new regulatory and administrative requirements. As a result, increases in the percentage of services
billed to government payers could have an adverse impact on our net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may experience temporary disruptions and delays in processing
biological samples at our facilities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may experience delays in processing biological
samples caused by software and other errors. Any delay in processing samples could have an adverse effect on our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our laboratories require ongoing CLIA certification.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The CLIA extended federal oversight to virtually
all clinical laboratories by requiring that they be certified by the federal government or by a federally-approved accreditation
agency. The CLIA requires that all clinical laboratories meet quality assurance, quality control and personnel standards. Laboratories
must also undergo proficiency testing and are subject to inspections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The sanctions for failure to comply with the
CLIA requirements include suspension, revocation or limitation of a laboratory&rsquo;s CLIA certificate, which is necessary to
conduct business, cancellation or suspension of the laboratory&rsquo;s approval to receive Medicare and/or Medicaid reimbursement,
as well as significant fines and/or criminal penalties. The loss or suspension of a CLIA certification, imposition of a fine or
other penalties, or future changes in the CLIA law or regulations (or interpretation of the law or regulations) could have a material
adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that we are in compliance with all
applicable laboratory requirements, but no assurances can be given that our laboratories will pass all future certification inspections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Failure to comply with HIPAA could be costly.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Health Insurance Portability and Accountability
Act, or HIPAA, and associated regulations protect the privacy and security of certain patient health information and establish
standards for electronic health care transactions in the United States. These privacy regulations establish federal standards regarding
the uses and disclosures of protected health information. Our Molecular Labs are subject to HIPAA and its associated regulations.
If we fail to comply with these laws and regulations we could suffer civil and criminal penalties, fines, exclusion from participation
in governmental health care programs and the loss of various licenses, certificates and authorizations necessary to operate our
Patient Testing business. We could also incur liabilities from third party claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our business could be adversely impacted by health care reform.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Government attention to the health care industry
in the United States is significant and may increase. The Patient Protection and Affordable Care Act passed by Congress and signed
into law by President Obama in March 2010 could adversely impact our business. While certain portions of the legislation have already
gone into effect, the ultimate impact of the legislation on the health care industry is still unknown, and the overall impact on
our business is likely to be extensive and could result in significant changes to our business and our customers&rsquo; businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are subject to a number of claims of various amounts that
arise out of the normal course of our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are subject to a number of claims of various
amounts that arise out of the normal course of our business. Specifically, on February 25, 2016, the Board of Regents of the University
of Nebraska, or UNMC, filed a lawsuit against us in the District Court of Douglas County, Nebraska for breach of contract and seeking
recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by
which to settle the outstanding liability. A $0.7 million liability has been recorded and is reflected in accrued expenses at December
31, 2015 and March 31, 2016. In addition, on April 13, 2016, Fox Chase Cancer Center, or Fox Chase, filed a <FONT STYLE="font-family: Times New Roman, Times, Serif">lawsuit</FONT>
against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division alleging,
among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment
and fraudulent conversion, conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates
to a license agreement we entered into with Fox Chase in August 2000, as amended, or the License Agreement, as well as the assignment
of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc., or IDT, pursuant to the Surveyor Kit
Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014, or the IDT Agreement.
Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox
Chase proceeding. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. Furthermore, there
is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our ongoing and future litigation could result
in significant additional costs and further divert the attention of our management and key personnel from our business operations
and the implementation of our business strategy. In addition, the disposition of any of the pending claims against us, in excess
of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may be subject to client lawsuits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Providers of clinical testing services may be
subject to lawsuits alleging negligence or other legal claims. Potential suits could involve claims for substantial damages. Litigation
could also have an adverse impact on our client base and our reputation. We maintain liability insurance coverage for certain claims
that could result from providing or failing to provide clinical testing services, including inaccurate testing results and other
exposures. Our insurance coverage limits our maximum recovery on individual claims and, therefore, there is no assurance that such
coverage will be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The sale of our products and business operations in international
markets subjects us to additional risks.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">During the past several years, international
sales have represented a significant portion of our total net sales. As a result, a major portion of our net sales are subject
to risks associated with international sales and operations. These risks include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Payment cycles in foreign markets are typically longer than in the
U.S., and capital spending budgets for research agencies can vary over time with foreign governments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in foreign currency exchange rates can make our products more
costly in local currencies because our foreign sales are typically paid for in British Pounds or in Euros;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The potential for changes in U.S. and foreign laws or regulations
that result in additional import or export restrictions, higher tariffs or other taxes, more burdensome licensing requirements
or similar impediments may limit our ability to sell products and services profitably in these markets; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The fluctuation of foreign currency exchange rates to the U.S. Dollar
and the Euro to the British Pound can cause our net sales and expenses to increase or decrease, which adds risk to our financial
statements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our dependence on our suppliers exposes us to certain risks.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We rely on various suppliers for products and
materials to produce our products. In the event that they would be unable to deliver these items due to product shortages or business
closures, we may be unable to deliver our products to our customers in a timely manner or may need to increase our prices. The
current economy poses the additional risk of our suppliers&rsquo; inability to continue their businesses as usual.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our markets are very competitive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Many of our competitors have greater resources
than we do and may enjoy other competitive advantages. This may allow them to more effectively market their products to our customers
or potential customers, to develop products that make our products obsolete or to produce and sell products less expensively than
us. As a result of these competitive factors, demand for and pricing of our products and services could be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our patents may not protect us from others using our technology,
which could harm our business and competitive position.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Patent law relating to the scope of claims in
the technology fields in which we operate is still evolving. The degree of future protection for our proprietary rights is uncertain.
Furthermore, we cannot be certain that others will not independently develop similar or alternative products or technology, duplicate
any of our products, or, if patents are issued to us, design around the patented products developed by us. Our patents or licenses
could be challenged by litigation and, if the outcome of such litigation were adverse to us, our competitors could be free to use
our technology. We may not be able to obtain additional patents for our technology, or if we are able to do so, patents may not
provide us with adequate protection or be commercially beneficial. In addition, we could incur substantial costs in litigation
if we are required to defend ourselves in patent suits brought by third parties or if we initiate such suits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We cannot be certain that other measures taken to protect our
intellectual property will be effective.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We rely upon trade secrets, copyright and trademark
laws, non-disclosure agreements and other contractual confidentiality provisions to protect some of our confidential and proprietary
information that we are not seeking patent protection for various reasons. Such measures, however, may not provide adequate protection
for our trade secrets or other proprietary information. If such measures do not protect our rights, third parties could use our
technology and our ability to compete in the market would be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are dependent upon licensed technologies and may need to obtain
additional licenses in the future to offer our products and remain competitive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have licensed key components of our technologies
from third parties. If these agreements were to terminate prematurely due to our breach of the terms of these licenses or we otherwise
fail to maintain our rights to such technologies, we may lose the right to manufacture or sell a substantial portion of our products.
In addition, we may need to obtain licenses to additional technologies in the future in order to keep our products competitive.
If we fail to license or otherwise acquire necessary technologies, we may not be able to develop new products that we need to remain
competitive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The protection of intellectual property in foreign countries
is uncertain.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A significant percentage of our sales are to
customers located outside the U.S. Patent and other intellectual property laws of some foreign countries may not protect our intellectual
property rights to the same extent as U.S.&nbsp;laws. We may need to bring proceedings to defend our patent rights or to determine
the validity of our competitors&rsquo; foreign patents. These proceedings could result in substantial cost and diversion of our
other efforts. Finally, some of the patent protections available to us in the U.S. are not available to us in foreign countries
due to the laws of those countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our products could infringe on the intellectual property rights
of others.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There are a significant number of U.S. and foreign
patents and patent applications submitted for technologies in, or related to, our area of business. As a result, our use of our
technology could infringe patents or proprietary rights of others. This may lead others to assert patent infringement or other
intellectual property claims against us. We could incur substantial costs in litigation if we are required to defend against intellectual
property claims by third parties. Additionally, any licenses that we might need as a result of any actual infringement might not
be available to us on commercially reasonable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our failure to comply with any applicable government laws and
regulations or otherwise respond to claims relating to improper handling, storage or disposal of hazardous chemicals that we use
may adversely affect our results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our research and development and manufacturing
activities involve the controlled use of hazardous materials and chemicals. We are subject to federal, state, local and international
laws and regulations governing the use, storage, handling and disposal of hazardous materials and waste products. If we fail to
comply with applicable laws or regulations, we could be required to pay penalties or be held liable for any damages that result
and this liability could exceed our financial resources. We cannot be certain that accidental contamination or injury will not
occur. Any such accident could damage our research and manufacturing facilities and operations, resulting in delays and increased
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may issue a substantial amount of our common stock to holders
of options and warrants and this could reduce the market price for our stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">At&nbsp;March&nbsp;31,
2016, we had obligations to issue&nbsp;12,970,881&nbsp;shares of common stock upon exercise of outstanding stock options, warrants
or conversion rights. The issuance of these securities may be dilutive to our current stockholders and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">could
negatively impact the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our common stock is thinly traded and a large percentage of our
shares are held by a small group of unrelated, institutional owners.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">At&nbsp;March 31, 2016, we had&nbsp;20,695,870&nbsp;shares
of common stock outstanding. The sale of a significant number of shares into the public market has the potential to cause significant
downward pressure on the price of our common stock. This is particularly the case if the shares being placed into the market exceed
the market&rsquo;s ability to absorb the stock. This presents an opportunity for short sellers to contribute to the further decline
of our stock price. If there are significant short sales of our stock, the price decline that would result from this activity will
cause the share price to decline more so, which, in turn, may cause long holders of the stock to sell their shares, thereby contributing
to sales of our stock in the market. In addition, the large concentration of our shares are held by a small group of stockholders
which could result in increased volatility in our stock price due to the limited number of shares available in the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have previously identified material weaknesses and ineffective
internal controls could impact our business and financial results.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our internal control over financial reporting
may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention
or overriding of controls, or fraud. In the course of auditing our financial statements as of and for the year ended December 31,
2014, our independent registered public accounting firm identified material weaknesses in our internal control over financial reporting
relating to proper timing and recognition of revenue and the elements used in our analysis and evaluation of the allowance for
doubtful accounts to ensure that the allowance for doubtful accounts is reasonably stated. We remediated these material weaknesses
in the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even effective internal controls can provide
only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we fail to maintain
the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience
difficulties in their implementation, our business and financial results could be harmed, we could fail to meet our financial reporting
obligations and we may not be able to accurately report financial results or prevent fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we cannot meet the continued listing requirements of The Nasdaq
Stock Market LLC, or Nasdaq, Nasdaq may delist our shares of common stock, which would have an adverse impact on the trading volume,
liquidity and market price of our common shares.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">On February
23, 2016, we received written notice, or the Notice, from Nasdaq indicating that, based on the closing bid price of our common
stock for the preceding 30 consecutive business days, we were not in compliance with the $1.00 minimum bid price requirement for
continued listing on the Nasdaq Capital Market, or the Minimum Bid Price Requirement, as set forth in Nasdaq Listing Rule 5550(a)(2).
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a period of 180 calendar days, or until August 22, 2016, to regain
compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of our common stock must meet or
exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">If we
are not in compliance with the Minimum Bid Price Requirement by August 22, 2016, Nasdaq may provide us with a second 180 calendar
day period to regain compliance. To qualify for the second 180 calendar day period, we would be required to (i) meet the continued
listing requirement for the Nasdaq Capital Market for market value of publicly held shares and all other initial listing standards
for the Nasdaq Capital Market, except for the Minimum Bid Price Requirement, and (ii) notify Nasdaq of our intent to cure our noncompliance
with the Minimum Bid Price, including by effecting a reverse stock split, if necessary. If we do not indicate our intent to cure
the deficiency or if it does not appear to Nasdaq that it would be possible for us to cure the deficiency, we would not be eligible
for the second 180 calendar day period, and our common stock would then be subject to delisting from the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">If we
do not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq
will provide</FONT> notice that our common stock will be subject to delisting. We would then be entitled to appeal the Nasdaq Staff&rsquo;s
determination to a Nasdaq Listing Qualifications Panel and request a hearing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On April 20, 2016, we&nbsp;received a second
written notice, or the Second Notice, from Nasdaq indicating that, based on the stockholders&rsquo; equity reported in our Annual
Report on Form 10-K, as filed with the SEC on April 14, 2016, we are not in compliance with the minimum stockholders&rsquo; equity
requirement for continued listing on the Nasdaq Capital Market, which requires listed companies to maintain stockholders&rsquo;
equity of at least $2,500,000, or the Minimum Stockholders&rsquo; Equity Requirement, as set forth in Nasdaq Listing Rule 5550(b)(1).
In accordance with Nasdaq Listing Rule 5810(c)(2)(C), we have a period of 45 calendar days, or until June 6, 2016, to submit a
plan to regain compliance with the Minimum Stockholders&rsquo; Equity Requirement. If our plan is accepted, Nasdaq may grant an
extension of up to 180 calendar days, or until October 17, 2016, to evidence compliance. If our plan is not accepted, we will have
the opportunity to appeal the Nasdaq Staff&rsquo;s determination to a Hearings Panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Neither
the First Notice nor the Second Notice has an immediate effect on the listing of our common stock, and our common stock will continue
to trade on the Nasdaq Capital Market under the symbol &ldquo;TBIO&rdquo; at this time. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to monitor the closing bid price of our common stock and consider our available options to resolve our noncompliance with
the Minimum Bid Price Requirement a</FONT>nd the Minimum Stockholders&rsquo; Equity Requirement<FONT STYLE="font-family: Times New Roman, Times, Serif">.
No determination regarding our response to the Notice has been made at this time. There can be no assurance that we will be able
to regain compliance with the Minimum Bid Price Requirement </FONT>or the Minimum Stockholders&rsquo; Equity Requirement&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">or
will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market. A suspension or delisting of our
common stock could adversely affect our relationships with our business partners and suppliers and customers&rsquo; and potential
customers&rsquo; decisions to purchase our products <FONT STYLE="background-color: white">and</FONT> services, and could have a
material, adverse impact on our business and operating results. In addition, a suspension or delisting could impair our ability
to raise additional capital through equity or debt financings and our ability to attract and retain employees by means of equity
compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the event of a delisting or suspension, our
common stock could begin trading on the over-the-counter bulletin board, or in the so-<FONT STYLE="background-color: white">called</FONT>
&ldquo;pink sheets.&rdquo; In the event of such trading, it is likely that there would be significantly less liquidity in the trading
of our common stock; decreases in institutional and other investor demand for our common stock, coverage by securities analysts,
market making activity and information available concerning trading prices and volume; and fewer broker-dealers willing to execute
trades in our common stock. The occurrence of any of these events could result in a further decline in the market price of our
common stock and could have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to this Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>You may experience immediate dilution in the book value per share
of the common stock you purchase. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior
to this </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">offering<FONT STYLE="background-color: white">. Assuming
that an aggregate of 5,833,333 shares of our common stock are sold during the term of the sales agreement with Craig-Hallum at
a price of $0.60 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on June 6, 2016, for
aggregate gross proceeds of </FONT></FONT>$3,500,000<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">,
after deducting commissions and estimated aggregate offering expenses payable by us, you will experience </FONT>immediate<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">
dilution of $</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">1.11<FONT STYLE="background-color: white"> per share,
representing the difference between our net tangible book value per share as of </FONT>March 31, 2016 <FONT STYLE="background-color: white">after
giving effect to this offering and the assumed offering price. The exercise of outstanding stock options and warrants may result
in further dilution of your investment. </FONT></FONT>For a further description of the dilution that you will experience immediately
after this offering, see the section in this prospectus supplement entitled &ldquo;Dilution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The actual number of shares we will issue under the Sales Agreement,
at any one time or in total, is uncertain.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Subject to certain limitations in the Sales
Agreement and compliance with applicable law, we have the discretion to deliver sales notices to Craig-Hallum at any time throughout
the term of the Sales Agreement. The number of shares that are sold by Craig-Hallum after delivering a sales notice will fluctuate
based on the market price of the common stock during the sales period and limits we set with Craig-Hallum. Because the price per
share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible
at this stage to predict the number of shares that will ultimately be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The market price of our common stock may be volatile and could
decline substantially.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The market price of our common stock has been
subject to wide fluctuations. From <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">January 1</FONT>,
2015 to June <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">6</FONT>, 2016, the closing price
of our common stock ranged from a low of $<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">0.50
</FONT>on <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">May 6</FONT>, 2016 to a high of $<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">3.90
</FONT>on <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">January 29</FONT>, 2015. The market
price of our common stock in the future is likely to continue to be subject to wide fluctuations in response to various factors,
including, but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>variations in our operating results and financial conditions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>actual or anticipated announcements of technical innovations, new product developments, or design wins by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general conditions in our industry; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>worldwide economic and financial conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, the public stock markets have experienced
extreme price and volume fluctuations that have particularly affected the market price for many technology companies and that have
often been unrelated to the operating performance of these companies. The broad market fluctuations and other factors may continue
to adversely affect the market price of our common stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Because we do not intend to pay dividends for the foreseeable
future, stockholders will benefit from an investment in our common stock only if it appreciates in value.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have never paid any cash dividends on our
common stock and do not expect to declare cash dividends on the common stock in the foreseeable <FONT STYLE="font-family: Times New Roman, Times, Serif">future</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">As</FONT> a result, the success of an investment in our common stock will
depend entirely upon any future appreciation. There is no guarantee that our common stock will appreciate in value or even maintain
the price at which shareholders have purchased their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have broad discretion to determine how to use the funds raised
in this offering, and may use them in ways that may not enhance our operating results or the price of our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our management will have broad discretion over
the use of proceeds from this offering, and we could spend the proceeds from this offering in ways our stockholders may not agree
with or that do not yield a favorable return, if at all. We intend to use the net proceeds of this offering for working capital
and general corporate purposes, which may include, without limitation, supporting asset growth and engaging in acquisitions or
other business combinations. We also may use a portion of the proceeds to repay debt. However, our use of these proceeds may differ
substantially from our current plans. If we do not invest or apply the proceeds of this offering in ways that improve our operating
results, we may fail to achieve expected financial results, which could cause our stock price to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_005"></A>DISCLOSURE
REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus supplement, the accompanying
prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E
of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. These
forward-looking statements are intended to be covered by the safe harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this prospectus
supplement, the accompanying prospectus or any document incorporated by reference in this prospectus supplement and the accompanying
prospectus regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and
plans and objectives of management are forward-looking statements. In some cases these statements are identifiable through the
use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;can,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo;
&ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of such terms and other similar expressions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These statements are based on management&rsquo;s
current views, assumptions or beliefs of future events and financial performance and are subject to uncertainty and changes in
circumstances. Readers of this prospectus supplement and the accompanying prospectus should understand that these statements are
not guarantees of performance or results and you are cautioned not to place undue reliance on these forward-looking statements.
Many factors could affect our actual financial results and cause them to vary materially from the expectations contained in the
forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables, operating
expenses, supplier pricing, availability and prices of raw materials, Medicare/Medicaid/Insurance reimbursements, product pricing,
the timing for introduction of new products, foreign currency exchange rates, sources of funding operations and acquisitions, our
ability to raise funds, sufficiency of available liquidity, future interest costs, future economic circumstances, business strategy,
industry conditions and key trends, our ability to execute our operating plans, the success of our cost savings initiatives, competitive
environment and related market conditions, expected financial and other benefits from our organizational restructuring activities,
actions of governments and regulatory factors affecting our business and other risks as described in our reports filed with the
SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should assume that the information appearing
in this prospectus, any accompanying prospectus supplement, any related free writing prospectus and any document incorporated herein
by reference is accurate as of its date only. New factors emerge from time to time, and it is not possible for us to predict which
factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We expressly disclaim any obligation to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently intend to use the net proceeds
from this offering for working capital and general corporate purposes, which may include, without limitation, supporting asset
growth and engaging in acquisitions or other business combinations. We also may use a portion of the proceeds to repay debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The amounts and timing of our use of the net
proceeds from this offering will depend on a number of factors, such as the timing and progress of our research and development
efforts, the timing and progress of any partnering and commercialization efforts, technological advances and the competitive environment
for our products. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for
the net proceeds to us from this offering. Accordingly, our management will have broad discretion in the timing and application
of these proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in
short-term, interest-bearing instruments. We reserve the right, at the sole discretion of our Board of Directors, to reallocate
the proceeds of this offering in response to developments in our business and any other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_007"></A><FONT STYLE="text-transform: uppercase"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If you invest in this offering, your ownership
interest will be diluted to the extent of the difference between the public offering price per share and the as adjusted net tangible
book value per share of our common stock after giving effect to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our net tangible book value as of <FONT STYLE="font-family: Times New Roman, Times, Serif">March
31, 2016 </FONT>was a deficit of $16,556,000, or ($0.80) per share of common stock. Our net tangible book value per share represents
total tangible assets less total liabilities, divided by the number of shares of common stock outstanding at <FONT STYLE="font-family: Times New Roman, Times, Serif">March
31, 2016</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">After giving effect to the assumed sale
of shares of our common stock in the aggregate amount of $3,500,000 at an assumed offering price of $0.60 per share, the last
reported sale price of our common stock on June 6, 2016, and after deduction of commissions and estimated offering expenses
payable by us, our as adjusted net tangible book value as of <FONT STYLE="font-family: Times New Roman, Times, Serif">March
31, 2016 </FONT>would have been a deficit of approximately $13,470,000, or ($0.51) per share of common stock. This amount
represents an immediate increase in as adjusted net tangible book value of $0.29 per share to our existing stockholders and
an immediate dilution in the as adjusted net tangible book value of approximately $1.11 per share to investors participating
in this offering at an assumed offering price of $0.60 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Dilution per share to new investors is determined
by subtracting the as adjusted net tangible book value per share after this offering from the public offering price per share
paid by purchasers in this offering. The following table illustrates this dilution on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">Assumed offering price per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 13.5pt">Net tangible book value per share as of <FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2016</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.80</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 13.5pt">Increase in as adjusted net tangible book value per
    share attributable to this offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.29</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">As adjusted net tangible book value per share after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.51</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Dilution per share to new investors participating in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.11</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
table above assumes for illustrative purposes that an aggregate of 5,833,333 shares of our common stock are sold during the term
of the Sales Agreement with Craig-Hallum at a price of $0.60 per share, the last reported sale price of our common stock on the
Nasdaq Capital Market on June 6</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">2016, for aggregate gross proceeds
of </FONT>$3,500,000<FONT STYLE="font-family: Times New Roman, Times, Serif">. Pursuant to the Sales Agreement with Craig-Hallum,
the shares are being sold from time to time at various prices. An increase of $0.50 per share in the price at which the shares
are sold from the assumed offering price of $0.60 per share shown in the table above, assuming all of our common stock in the
aggregate amount of $3,500,000 during the term of the sales agreement with Craig-Hallum is sold at that price, would increase
our pro forma net tangible book value per share after the offering to ($0.40) per share and would decrease the dilution in net
tangible book value per share to new investors in this offering to $1.00 per share, after deducting commissions and estimated
aggregate offering expenses payable by us. A decrease of $0.50 per share in the price at which the shares are sold from the assumed
offering price of $0.60 per share shown in the table above, assuming all of our common stock in the aggregate amount of $3,500,000
during the term of the Sales Agreement with Craig-Hallum is sold at that price, would decrease our pro forma net tangible book
value per share after the offering to ($0.61)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">per share and
would increase the dilution in net tangible book value per share to new investors in this offering to $1.21 per share, after
deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes
only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The <FONT STYLE="font-family: Times New Roman, Times, Serif">amounts
</FONT>above are based on 20,695,870 shares of common stock outstanding as of <FONT STYLE="font-family: Times New Roman, Times, Serif">March
31, 2016 </FONT>and do not take into account, as of <FONT STYLE="font-family: Times New Roman, Times, Serif">March 31, 2016</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></td>
    <td style="font-size: 10pt">1,121,794 shares of our common stock issuable upon exercise of outstanding stock options to purchase
    shares of our common stock at a weighted average exercise price of $3.42 per share;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></td>
    <td style="font-size: 10pt">98,333 shares of our common stock issuable upon exercise of outstanding stock appreciation rights
    with a weighted average exercise price of $4.14 per share;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></td>
    <td style="font-size: 10pt">371,275 shares of our common stock reserved for issuance under our 2006 Equity Incentive Plan,
    as amended;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></td>
    <td style="font-size: 10pt">2,365,243 shares of our Series A-1 Convertible Preferred Stock, which is convertible into shares
    of our common stock at a rate of 1-for-1, subject to certain adjustments;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></td>
    <td style="font-size: 10pt">8,853,905 shares of our common stock issuable in connection with our outstanding warrants with
    a weighted average exercise price of $3.10 per share; and</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></td>
    <td style="font-size: 10pt">shares of our common stock issuable upon conversion of our unsecured outstanding convertible promissory
    notes in the aggregate principal amount of $571,250.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have entered into a
sales agreement, dated June 7, 2016, with Craig-Hallum, that provides for the issuance and sale by us of shares of our common stock
having an aggregate offering price of up to $3,500,000 from time to time through Craig-Hallum acting as agent. This prospectus
supplement relates to the offer and sale of such shares of common stock under such Sales Agreement under the registration statement
of which this prospectus supplement forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Upon instructions from us, Craig-Hallum will
use its commercially reasonable efforts, consistent with its normal sales and trading practices and applicable law, to sell shares
of our common stock under the Sales Agreement pursuant to this prospectus supplement. Sales of the shares of common stock, if any,
pursuant to this prospectus supplement will be made in an &ldquo;at the market offering&rdquo; as defined in Rule 415 under the
Securities Act. Specifically, sales will be made directly on the Nasdaq Capital Market, the existing trading market for the common
stock, or on any other existing trading market for our common stock, at market prices prevailing at the time of sale. In the event
any sales are made pursuant to the Sales Agreement which are not made directly on the Nasdaq Capital Market or on any other existing
trading market for our common stock at market prices at the time of sale, including, without limitation, any sales to the sales
agent acting as principal or sales in privately negotiated transactions, we will file a prospectus supplement describing the terms
of such transaction, the amount of shares sold, the price thereof, the applicable compensation, and such other information as may
be required pursuant to Rule 424 and Rule 430B under the Securities Act, as applicable, within the time required by Rule 424 under
the Securities Act. To the extent required by Regulation&nbsp;M, Craig-Hallum will not engage in any transactions that stabilize
our common stock while the offering is ongoing under this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the Sales Agreement between us and Craig-Hallum,
we will instruct Craig-Hallum in a sales notice as to the maximum amount of shares of our common stock to be sold by Craig-Hallum
daily, and the minimum price per share at which such shares may be sold. Subject to the conditions of the Sales Agreement, Craig-Hallum
will use its commercially reasonable efforts to solicit purchases on a particular day of all shares designated for sale by us on
that day. The gross sales price of the shares sold will be the market price for shares of our common stock sold by Craig-Hallum
on the trading market at the time of sale of the shares. We or Craig-Hallum may suspend the offering of our common stock upon proper
notice and subject to certain other conditions. The obligation of Craig-Hallum under the Sales Agreement to sell our common stock
pursuant to a sales notice is subject to a number of customary conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Craig-Hallum will provide written confirmation
to us following the close of trading on the Nasdaq Capital Market following each day in which shares of our common stock are sold
under the Sales Agreement. Each confirmation will include the number of shares sold on the day, the aggregate gross sales proceeds,
the net proceeds to us and the compensation payable by us to Craig-Hallum with respect to the sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will pay Craig-Hallum commissions for its
services in acting as our agent in the sale of our common stock. The compensation payable to Craig-Hallum for sales of shares of
our common stock with respect to which Craig-Hallum acts as sales agent shall be equal to 3.25% of the gross sales price of those
shares. There is no guarantee that there will be any sales of our common stock under this prospectus supplement and the accompanying
base prospectus and actual sales, if any, of our common stock under this prospectus supplement and the accompanying base prospectus
may result in gross proceeds to us of less than $3,500,000, exclusive of any sales agent compensation or other offering fees and
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Settlement for sales of shares of our common
stock will occur on the third business day following the date on which any sales are made. There is no arrangement for funds to
be received in an escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the sale of shares of
our common stock on our behalf, Craig-Hallum may be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the
Securities Act, and the compensation of Craig-Hallum may be deemed to be underwriting commissions or discounts. We have <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">also</FONT>
agreed to reimburse Craig-Hallum for certain specified expenses, including the fees and disbursements of its legal counsel in
an amount of    $55,000, a $25,000 non-accountable expense allowance for Craig-Hallum&rsquo;s due diligence fees and
out-of-pocket due diligence fees not to exceed $5,000 per calendar quarter. We have agreed to provide indemnification and
contribution to Craig-Hallum with respect to certain civil liabilities, including liabilities under the Securities Act and
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We estimate that the total expenses of the offering
payable by us, excluding commissions payable to Craig-Hallum under the Sales Agreement, will be approximately $300,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The offering of shares of our common stock pursuant
to the Sales Agreement will terminate upon the earlier of (1) the sale of all of our common stock provided for in this prospectus
supplement, or (2) the termination of the Sales Agreement. The Sales Agreement may be terminated by us at any time in our sole
discretion by giving fifteen business days&rsquo; written notice to Craig-Hallum, or by Craig-Hallum at any time in its sole discretion.
The Sales Agreement will remain in full force and effect until the earlier of one year from the date thereof and such date that
the Sales Agreement is terminated in accordance with the terms thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This is a brief summary of the material provisions
of the Sales Agreement and does not purport to be a complete statement of its terms and conditions. A copy of the Sales Agreement
has been filed with the SEC on a Current Report on Form 8-K and is incorporated by reference into the registration statement of
which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Craig-Hallum and its affiliates may in the future
provide various investment banking and other financial services for us for which services they may in the future receive customary
fees. The principal business address of Craig-Hallum is 222 South Ninth Street, Suite 350, Minneapolis, MN 55402.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_009"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Certain legal matters relating to the issuance
of the securities offered by this prospectus supplement will be passed upon for us by Paul Hastings LLP, Palo Alto, California.
Craig-Hallum Capital Group LLC is being represented in connection with this offering by Ellenoff Grossman &amp; Schole LLP, New
York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_010"></A><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The consolidated balance sheets of Transgenomic,
Inc. and Subsidiary (the &ldquo;Company&rdquo;) as of December 31, 2015 and 2014, and the related consolidated statements of operations,
comprehensive loss, stockholders&rsquo; equity and cash flows for each of the two years in the period ended December 31, 2015 appearing
in Transgenomic, Inc.&rsquo;s Annual Report (Form 10-K) for the year ended December 31, 2015, have been audited by Ernst &amp;
Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph
that raises substantial doubt about the Company&rsquo;s ability to continue as a going concern as described in Note 1 to the consolidated
financial statements), included therein, and incorporated herein by reference. Such financial statements are incorporated herein
in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_011"></A><FONT STYLE="text-transform: uppercase"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are subject to the information reporting
requirements of the Exchange Act, and we file annual, quarterly and special reports, proxy statements and other <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">information</FONT>
with the SEC relating to our business, financial results and other matters. The reports, proxy statements and other information
we file may be inspected and copied at prescribed rates at the SEC&rsquo;s Public Reference Room and via the SEC&rsquo;s website
(see below for more information).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus supplement and the accompanying
prospectus are part of a registration statement on Form S-3 that we filed under the Securities Act with the SEC. This prospectus
supplement and the accompanying prospectus do not contain all of the information included in that registration statement and its
accompanying exhibits and schedules. For further information with respect to our securities and us, you should refer to that registration
statement and its accompanying exhibits and schedules. Statements in this prospectus supplement and the accompanying prospectus
concerning any document that we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not
intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate
these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You may inspect a copy of the registration statement
of which this prospectus supplement is a part and its accompanying exhibits and schedules, as well as the reports, proxy statements
and other information we file with the SEC, without charge at the SEC&rsquo;s Public Reference Room, 100 F Street, N.E., Room 1580,
Washington, D.C. 20549, and you may obtain copies of all or any part of the registration statement from those offices for a fee.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains
a web site that contains reports, proxy and information statements and other information regarding registrants that file electronically,
including us. The address of the site is <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_012"></A><FONT STYLE="text-transform: uppercase"><B>INFORMATION
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information into this prospectus, which means that we can disclose important information to you by referring you to another document
filed separately with the SEC. The documents incorporated by reference into this prospectus contain important information that
you should read about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following documents
are incorporated by reference into this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>The Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on April
14, 2016;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>The Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 23, 2016;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>The Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 29, 2016;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>The Registrant&rsquo;s Current Reports on Form 8-K filed with the SEC on (i) January 11, 2016, filed at 7:30 a.m. Eastern Time,
(ii) January 11, 2016, filed at 7:33 a.m. Eastern Time, (iii) January 20, 2016, (iv) February 26, 2016, (v) March 14, 2016, and
(vi) April 26, 2016; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD>The description of the Registrant&rsquo;s common stock set forth in the Registrant&rsquo;s Registration Statement on Form 8-A
(File No. 001-36439), filed with the SEC on May 5, 2014, including any amendments or reports filed for the purpose of updating
such description.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also incorporate by reference any future
filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are
related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which
this prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that
indicates the termination of the offering of the securities made by this prospectus and will become a part of this prospectus from
the respective dates that such documents are filed with the SEC. Any statement contained herein or in a document incorporated or
deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof or of the related
prospectus supplement to the extent that a statement contained herein or in any other subsequently filed document which is also
incorporated or deemed to be incorporated herein modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Documents incorporated
by reference are available from us, without charge. You may obtain documents incorporated by reference in this prospectus by requesting
them in writing or by telephone at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Transgenomic, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Attn: Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">12325 Emmet Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Omaha, Nebraska 68164</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Phone: (402) 452-5400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Fax: (402) 452-5461</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">E-mail: investorrelations@transgenomic.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 30%; text-align: left; vertical-align: middle"><b>PROSPECTUS</b></td>
    <TD STYLE="vertical-align: top; width: 40%; text-align: center"><IMG SRC="tlogo2.jpg" ALT=""></td>
    <TD STYLE="vertical-align: top; width: 30%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Transgenomic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$50,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">We may offer and sell up to $50,000,000 in the
aggregate of any combination of the securities identified above from time to time in one or more offerings, either individually
or in combination with other securities. We may also offer common stock or preferred stock upon conversion of debt securities,
common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each time we offer and sell securities, we will
provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms
of the securities. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings.
The prospectus supplement and any related free writing prospectuses may also add, update or change information contained in this
prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement and
any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may offer and sell the securities described
in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers,
or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities,
their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth,
or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus
entitled &ldquo;About this Prospectus&rdquo; and &ldquo;Plan of Distribution&rdquo; for more information. No securities may be
sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering
of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Investing in our securities involves a
high degree of risk. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo;
on page 2 of this prospectus, any applicable prospectus supplement and in any applicable free writing prospectuses, and under similar
headings in the documents that are incorporated by reference into this prospectus.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our common stock is currently listed on the
NASDAQ Capital Market under the symbol &ldquo;TBIO&rdquo;. On February 3, 2015, the last reported sales price for our common stock
was $3.32 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on
the NASDAQ Capital Market or any securities market or other exchange of the securities, if any, covered by the applicable prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is February 13,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 95%"><A HREF="#b_001">About This Prospectus</A></td>
    <td style="width: 5%; text-align: right">1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_002">Prospectus Summary</A></td>
    <td style="text-align: right">1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_003">Risk Factors</A></td>
    <td style="text-align: right">2</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_004">Disclosure Regarding Forward-Looking Statements</A></td>
    <td style="text-align: right">3</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_005">Use of Proceeds</A></td>
    <td style="text-align: right">3</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_006">Ratio of Earnings to Fixed Charges and Preferred Share Dividends</A></td>
    <td style="text-align: right">4</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_007">Description of Capital Stock</A></td>
    <td style="text-align: right">4</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_008">Description of Debt Securities</A></td>
    <td style="text-align: right">8</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_009">Description of Warrants</A></td>
    <td style="text-align: right">15</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_010">Description of Units</A></td>
    <td style="text-align: right">17</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_011">Legal Ownership of Securities</A></td>
    <td style="text-align: right">17</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_012">Plan of Distribution</A></td>
    <td style="text-align: right">20</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_013">Legal Matters</A></td>
    <td style="text-align: right">22</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_014">Experts</A></td>
    <td style="text-align: right">22</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_015">Where You Can Find More Information</A></td>
    <td style="text-align: right">22</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#b_016">Important Information Incorporated by Reference</A></td>
    <td style="text-align: right">22</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus is part of a registration statement
on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &ldquo;shelf&rdquo; registration
process. Under this shelf registration process, we may offer and sell shares of our common stock and preferred stock, various series
of debt securities, warrants to purchase any of such securities and/or units consisting of any combination of such securities,
either individually or in combination with other securities, in one or more offerings, up to a total dollar amount of $50,000,000.
This prospectus provides you with a general description of the securities we may offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each time we offer securities under this prospectus,
we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also
authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings.
The prospectus supplement and any related free writing prospectus we have authorized for use in connection with a specific offering
may also add, update or change any of the information contained in this prospectus or in the documents that we have incorporated
by reference into this prospectus. We urge you to read carefully this prospectus, any applicable prospectus supplement and any
free writing prospectuses we have authorized for use in connection with a specific offering, together with the information incorporated
herein by reference as described under the section entitled &ldquo;Important Information Incorporated by Reference&rdquo;, before
buying any of the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should rely only on the information contained
in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the information contained
in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone
to provide you with different or additional information. This prospectus is an offer to sell only the securities offered hereby,
but only under circumstances and in jurisdictions where it is lawful to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The information appearing in this prospectus,
any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the
document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by
reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing
prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed
since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus contains summaries of certain
provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein
have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus
is a part, and you may obtain copies of those documents as described below under the heading &ldquo;Where You Can Find More Information&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="b_002"></A><B>PROSPECTUS
SUMMARY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>This summary highlights selected information
contained elsewhere in this prospectus or incorporated by reference in this prospectus, and does not contain all of the information
that you need to consider in making your investment decision. You should carefully read the entire prospectus, any applicable prospectus
supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading
&ldquo;Risk Factors&rdquo; contained in any applicable prospectus supplement and any related free writing prospectus, and under
similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read
the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration
statement of which this prospectus is a part. Unless otherwise mentioned or unless the context requires otherwise, all references
in this prospectus to &ldquo;Transgenomic&rdquo;, &ldquo;the Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;
or similar references mean Transgenomic, Inc. together with its consolidated subsidiary.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Transgenomic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a global biotechnology company advancing
personalized medicine in the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies
and clinical and research services. We have two complementary business segments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Laboratory Services. Our laboratories specialize in genetic testing for cardiology, neurology, mitochondrial disorders and
oncology. Our Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical
Laboratory Improvement Amendment as high complexity labs and our Omaha facility is also accredited by the College of American Pathologists.
Our Biomarker Identification laboratory located in Omaha, Nebraska also provides pharmacogenomics research services supporting
Phase II and Phase III clinical trials conducted by pharmaceutical companies. Our laboratories employ a variety of genomic testing
service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any
laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type,
including tissue biopsies, blood, cell-free DNA and circulating tumor cells at levels greater than 1,000-fold higher than standard
DNA sequencing techniques.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Genetic Assays and Platforms. Our proprietary product is the WAVE&reg; System, which has broad applicability to genetic variation
detection in both molecular genetic research and molecular diagnostics. We also distribute bioinstruments produced by other manufacturers,
or OEM Equipment, through our sales and distribution network. Service contracts to maintain installed systems are sold and supported
by our technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables
that are required for the continued operation of the bioinstruments. We develop, manufacture and sell these consumable products.
In addition, we manufacture and sell consumable products that can be used on multiple, independent platforms. These products include
a range of chromatography columns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For a complete description of our business,
financial condition, results of operations and other important information, we refer you to our filings with the Securities and
Exchange Commission, or the SEC, that are incorporated by reference in this prospectus, including our Annual Report on Form 10-K
for the year ended December 31, 2013. For instructions on how to find copies of these documents, see &ldquo;Where You Can Find
More Information&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We were incorporated in Delaware on March 6,
1997. Our principal office is located at 12325 Emmet Street, Omaha, Nebraska 68164 and our telephone number is 402-452-5400. Our
website address is <U>www.transgenomic.com</U>. Information on our website, or that can be accessed through our website, is not
incorporated by reference into this prospectus and does not constitute part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_003"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Investing in any securities offered pursuant
to this prospectus and the applicable prospectus supplement involves a high degree of risk. Before making an investment decision,
you should carefully consider the risks described under &ldquo;Risk Factors&rdquo; in any applicable prospectus supplement and
in our most recent Annual Report on Form 10-K, or any updates in our Quarterly Reports on Form 10-Q, together with all of the other
information appearing in or incorporated by reference into this prospectus and any applicable prospectus supplement, before deciding
whether to purchase any of the securities being offered. Our business, financial condition or results of operations could be materially
adversely affected by any of these risks. The occurrence of any of these risks might cause you to lose all or part of your investment
in the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_004"></A><FONT STYLE="text-transform: uppercase"><B>DISCLOSURE
REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus and the documents incorporated
by reference into this prospectus may contain forward-looking statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, about the Company and its subsidiaries. These forward-looking statements are intended to be covered by the safe harbor for
forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not
statements of historical fact, and can be identified by the use of forward-looking terminology such as &ldquo;believes&rdquo;,
&ldquo;expects&rdquo;, &ldquo;may&rdquo;, &ldquo;will&rdquo;, &ldquo;could&rdquo;, &ldquo;should&rdquo;, &ldquo;projects&rdquo;,
&ldquo;plans&rdquo;, &ldquo;goal&rdquo;, &ldquo;targets&rdquo;, &ldquo;potential&rdquo;, &ldquo;estimates&rdquo;, &ldquo;pro forma&rdquo;,
&ldquo;seeks&rdquo;, &ldquo;intends&rdquo; or &ldquo;anticipates&rdquo; or the negative thereof or comparable terminology. Forward-looking
statements include discussions of strategy, financial projections, guidance and estimates (including their underlying assumptions),
statements regarding plans, objectives, expectations or consequences of various transactions, and statements about the future performance,
operations, products and services of the Company and its subsidiaries. We caution our stockholders and other readers not to place
undue reliance on such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should read this prospectus and the documents
incorporated by reference completely and with the understanding that our actual future results may be materially different from
what we currently expect. Our business and operations are and will be subject to a variety of risks, uncertainties and other factors.
Consequently, actual results and experience may materially differ from those contained in any forward-looking statements. Such
risks, uncertainties and other factors that could cause actual results and experience to differ from those projected include, but
are not limited to, the risk factors set forth in Part I - Item 1A, &ldquo;Risk Factors&rdquo;, in our Annual Report on Form 10-K
for the year ended December 31, 2013, as filed with the SEC on March 27, 2014, and elsewhere in the documents incorporated by reference
into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should assume that the information appearing
in this prospectus, any accompanying prospectus supplement, any related free writing prospectus and any document incorporated herein
by reference is accurate as of its date only. Because the risk factors referred to above could cause actual results or outcomes
to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue
reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made.
New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot
assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking statements. All written or oral forward-looking statements
attributable to us or any person acting on our behalf made after the date of this prospectus are expressly qualified in their entirety
by the risk factors and cautionary statements contained in and incorporated by reference into this prospectus. Unless legally required,
we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances
after the date of this prospectus or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="b_005"></A><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Except as described in any applicable prospectus
supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently
intend to use the net proceeds from this offering, if any, for working capital and general corporate purposes, which may include,
without limitation, supporting asset growth and engaging in acquisitions or other business combinations. We also may use a portion
of the proceeds to repay debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The amounts and timing of our use of the net
proceeds from this offering will depend on a number of factors, such as the timing and progress of our research and development
efforts, the timing and progress of any partnering and commercialization efforts, technological advances and the competitive environment
for our products. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds
to us from this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds.
Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in short-term, interest-bearing
instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_006"></A><FONT STYLE="text-transform: uppercase"><B>RATIO
OF EARNINGS TO FIXED CHARGES AND PREFERRED SHARE DIVIDENDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the historical ratios of earnings to fixed charges and preferred share dividends for Transgenomic and its subsidiary for
the periods indicated.<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</td>
    <TD COLSPAN="14" NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</td>
    <TD COLSPAN="2" NOWRAP STYLE="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Nine Months</b></font><br>
<font style="font-size: 10pt"><b>Ended</b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<tr>
    <TD NOWRAP STYLE="vertical-align: bottom"><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <TD COLSPAN="2" NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2009 </b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <TD COLSPAN="2" NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2010 </b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <TD COLSPAN="2" NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2011 </b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <TD COLSPAN="2" NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2012 </b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <TD COLSPAN="2" NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2013 </b></font></td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2014</b></font></td>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 57%; padding-left: 10pt; text-indent: -10pt">Ratio of earnings (loss) to fixed charges(1)</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%; text-align: right">-</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 5%; text-align: right">-</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 1%; text-align: right"></td>
    <TD STYLE="width: 5%; text-align: right">-</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 5%; text-align: right">-</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 5%; text-align: right">-</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 5%; text-align: right">-</td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Ratio of earnings (loss) to combined fixed charges and preferred share dividends(2)</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right"></td>
    <TD STYLE="text-align: right">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">-</td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">(1) We did not record earnings for any of the
years ended December 31, 2009, 2010, 2011, 2012 or 2013 or the nine months ended September 30, 2014. Accordingly, our earnings
were insufficient to cover fixed charges for such periods and we are unable to disclose a ratio of earnings to fixed charges for
such periods. The dollar amount of the deficiency in earnings available for fixed charges for the years ended December 31, 2009,
2010, 2011, 2012 and 2013 and the nine months ended September 30, 2014 was approximately $1.878 million, $2.984 million, $9.737
million, $8.181 million, $16.041 million and $7.678 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">(2) We did not record earnings for any of the
years ended December 31, 2009, 2010, 2011, 2012 or 2013 or the nine months ended September 30, 2014. Accordingly, our earnings
were insufficient to cover combined fixed charges and preference dividends for such periods and we are unable to disclose a ratio
of earnings to combined fixed charges and preference dividends for such periods. The dollar amount of the deficiency in earnings
available for combined fixed charges and preference dividends for the years ended December 31, 2009, 2010, 2011, 2012 and 2013
and the nine months ended September 30, 2014 was approximately $1.878 million, $2.984 million, $10.747 million, $8.841 million,
$16.767 million and $8.517 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_007"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under our Third Amended and Restated Certificate
of Incorporation, as amended from time to time, or the Certificate of Incorporation, we are authorized to issue up to 150,000,000
shares of common stock, $0.01 par value per share, or the Common Stock, from time to time, as provided in a resolution or resolutions
adopted by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of January 31, 2015, 8,283,179 shares of
Common Stock were issued and outstanding, held by approximately 82 stockholders of record, not including beneficial holders whose
shares are held in names other than their own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Dividends, Voting Rights and Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Holders of Common Stock are entitled to one
vote for each share held of record on all matters submitted to a vote of the stockholders and do not have cumulative voting rights.
Holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our Board
of Directors out of funds legally available for dividend payments. All outstanding shares of Common Stock are fully paid and non-assessable.
The holders of Common Stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights. There
are no redemption or sinking fund provisions applicable to the Common Stock. In the event of any liquidation, dissolution or winding-up
of our affairs, holders of Common Stock will be entitled to share ratably in our assets that are remaining after payment or provision
for payment of all of our debts and obligations. The rights, preferences and privileges of the Common Stock are subject to, and
may be adversely affected by, the rights of the holders of shares of any series of preferred stock currently outstanding or which
we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>General Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the Certificate of Incorporation, we have
the authority to issue up to 15,000,000 shares of preferred stock, $0.01 par value per share, or the &ldquo;Preferred Stock&rdquo;,
issuable in specified series and having specified voting, dividend, conversion, liquidation and other rights and preferences as
our Board of Directors may determine, subject to limitations set forth in the Certificate of Incorporation. The Preferred Stock
may be issued for any lawful corporate purpose without further action by our stockholders. The issuance of any Preferred Stock
having conversion rights might have the effect of diluting the interests of our other stockholders. In addition, shares of Preferred
Stock could be issued with rights, privileges and preferences which would deter a tender or exchange offer or discourage the acquisition
of control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Of the number of shares of Preferred Stock authorized
by our Certificate of Incorporation, as of January 31, 2015 (i) 3,879,307 shares had been designated Series A Convertible Preferred
Stock with such rights, privileges and preferences as set forth in the Certificate of Amendment of Certificate of Designation of
Series A Convertible Preferred Stock filed with the Secretary of State of the State of Delaware on March 5, 2014, or the Series
A Certificate of Designation, and (ii) 1,443,297 shares had been designated Series B Convertible Preferred Stock with such rights,
privileges and preferences as set forth in the Certificate of Designation of Series B Convertible Preferred Stock filed with the
Secretary of State of the State of Delaware on March 5, 2014, or the Series B Certificate of Designation. As of January 31, 2015,
2,586,205 shares of the Series A Convertible Preferred Stock, or the Series A Preferred, were issued and outstanding, and 1,443,297
shares of the Series B Convertible Preferred Stock, or the Series B Preferred, were issued and outstanding. The Series A Preferred
and the Series B Preferred are sometimes referred to in this prospectus, together, as the Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Dividends, Voting Rights and Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each of the Series A Certificate of Designation
and the Series B Certificate of Designation provides that the holders of Preferred Shares shall be entitled, as a separate voting
group, at each annual or special election of directors, to elect two directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Certain rights of the holders of the Series
B Preferred are senior to the rights of the holders of the Series A Preferred and to the rights of the holders of our Common Stock.
The Series B Preferred has a liquidation preference equal to its original price per share, plus any accrued and unpaid dividends
thereon. The Series B Preferred accrues cumulative dividends at the rate of 6.0% of the original price per share per annum. Additionally,
the Series B Certificate of Designation also contains an optional redemption provision whereby the holders of a majority of the
then issued and outstanding Series B Preferred, voting together as a separate class, may, after March 5, 2019, the fifth anniversary
of the closing of the private placement in which the shares of Series B Preferred were issued, require the Company to redeem all
of the then issued and outstanding shares of Series B Preferred at the initial price per share of the Series B Preferred, as adjusted
for any stock dividends, combinations or splits, plus all accrued but unpaid dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Certain rights of the holders of the Series
A Preferred are senior to the rights of the holders of our Common Stock. Subject to the liquidation preference of the Series B
Preferred, the Series A Preferred has a liquidation preference equal to its original price per share, plus any accrued and unpaid
dividends thereon. After the payment of dividends to the holders of Series B Preferred, the Series A Preferred accrues cumulative
dividends at the rate of 10.0% of the original price per share per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">All outstanding shares of Series B Preferred
will be automatically converted into Common Stock, at an initial conversion rate of 1:1, and all outstanding shares of Series A
Preferred will be automatically converted into Common Stock, at an initial conversion rate of 4:1, at the election of the holders
of a majority of the then-outstanding Preferred Shares, voting together as a single class on an as-converted to Common Stock basis.
The initial conversion rate for each of the Series A Preferred and the Series B Preferred is subject to adjustment in the event
of certain stock splits, stock dividends, mergers, reorganizations and reclassifications. After giving effect to the 1-for-12 reverse
split of the Common Stock effected in January 2014, the conversion rate for the Series A Preferred was adjusted to 1:3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Generally, the holders of the Preferred Shares
are entitled to vote together as a single group with the holders of Common Stock on an as-converted to Common Stock basis. However,
each of the Series A Certificate of Designation and the Series B Certificate of Designation provides that we will not perform the
following activities, subject to certain exceptions, without the affirmative vote of the holders of at least two-thirds of the
outstanding Preferred Shares, voting together as a single class on an as-converted to Common Stock basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorize, create or issue any other class or series of capital stock having rights, preferences or privileges senior to or
in parity with the Preferred Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>alter or change the rights, preferences or privileges of the Preferred Shares or increase or decrease the authorized number
of Preferred Shares, Series A Preferred or Series B Preferred;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorize or declare any dividends on the shares of Common Stock or any other shares of capital stock other than the Preferred
Shares, other than dividends payable solely in shares of Common Stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorize any offering of equity securities of the Company representing (on a pro forma basis after giving effect to the issuance
of such equity securities) the right to receive not less than 10% of any amounts or funds that would, as of immediately following
such issuance, be legally available for distribution in connection with a liquidation event;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>redeem any shares of capital stock (other than pursuant to employee agreements or the terms of the capital stock);</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increase or decrease the authorized number of members of the Board of Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>enter into any binding agreement with any director, employee or any affiliate of the Company, excluding employment-related
and equity award agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>materially change the nature of the Company&rsquo;s business, enter into new lines of business or exit the current line of
business or invest in any person or entity engaged in a business that is not substantially similar to the Company&rsquo;s business,
or change the location of any permanent location of any part of the Company&rsquo;s business;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>make any loans or advances, individually or in the aggregate in excess of $1,000,000, to, or own any securities of, any subsidiary
or other corporation or other entity unless it is wholly owned by the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>make any loan or advance to any natural person, including, without limitation, any employee or director of the Company, except
advances and similar expenditures in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>guarantee, directly or indirectly, any indebtedness, except for trade accounts of the Company arising in the ordinary course
of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>sell or otherwise dispose of any assets of the Company with a value, individually or collectively, in excess of $500,000, other
than in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>liquidate, dissolve or wind-up the business and affairs of the Company or effect a change in control or any other liquidation
event;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>incur any indebtedness in excess of $1,000,000 in the aggregate, other than trade credit incurred in the ordinary course of
business;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expend funds in excess of $500,000 in the aggregate per year for capital improvements, other than any such expenditure that
is consistent with a budget approved by the Board of Directors, including the directors elected by the holders of Preferred Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obligate the Company to make aggregate annual payments in excess of $500,000 or sell, transfer, pledge or license any material
technology or intellectual property of the Company, other than a non-exclusive license in the ordinary course of business; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increase the number of shares reserved and issuable under any of the Company&rsquo;s equity or option incentive compensation
plans.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Anti-Takeover Effects Under Section 203 of the General Corporation
Law of the State of Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are subject to Section 203 of the General
Corporation Law of the State of Delaware, or the DGCL, which prohibits a Delaware corporation from engaging in any business combination
with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder,
with the following exceptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>before such date, the board of directors of the corporation approved either the business combination or the transaction that
resulted in the stockholder becoming an interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes
of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares
owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have
the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or an exchange offer;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on or after such date, the business combination is approved by the board of directors and authorized at an annual or a special
meeting of the stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock
that is not owned by the interested stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In general, Section 203 of the DGCL defines
&ldquo;business combination&rdquo; to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any merger or consolidation involving the corporation or any direct or indirect majority owned subsidiary of the corporation
and the interested stockholder or any other corporation, partnership, unincorporated association, or other entity if the merger
or consolidation is caused by the interested stockholder and as a result of such merger or consolidation the transaction is not
excepted as described above;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any sale, transfer, pledge, or other disposition (in one transaction or a series) of 10% or more of the assets of the corporation
involving the interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of
the corporation to the interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class
or series of the corporation beneficially owned by the interested stockholder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges, or other financial benefits
by or through the corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In general, Section 203 of the DGCL defines
an &ldquo;interested stockholder&rdquo; as an entity or a person who, together with the person&rsquo;s affiliates and associates,
beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more
of the outstanding voting stock of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A Delaware corporation may &ldquo;opt out&rdquo;
of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate
of incorporation or bylaws resulting from a stockholders&rsquo; amendment approved by at least a majority of the outstanding voting
shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may
be discouraged or prevented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Anti-Takeover Effects Under Certain Provisions of our Certificate
of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our Certificate of Incorporation and our Amended
and Restated Bylaws, or the Bylaws, include a number of provisions that may have the effect of deterring hostile takeovers or delaying
or preventing changes in control of the management of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">First, our Certificate of Incorporation provides
that all stockholder actions must be effected at a duly called meeting of holders and not by a consent in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Second, our Bylaws provide that special meetings
of the holders may be called only by the chairman of our Board of Directors, the Chief Executive Officer or our Board of Directors
pursuant to a resolution adopted by a majority of the total number of authorized directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Third, our Certificate of Incorporation provides
that our Board of Directors can issue up to 15,000,000 shares of Preferred Stock without further action by our stockholders, as
described under &ldquo;&mdash;Preferred Stock&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Fourth, our Certificate of Incorporation and
Bylaws provide for a classified Board of Directors in which approximately one-third of the directors are elected each year. Consequently,
any potential acquirer would need to successfully complete two proxy contests in order to take control of our Board of Directors.
As a result of the provisions of the Certificate of Incorporation and Delaware law, stockholders will not be able to cumulate votes
for directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Fifth, our Certificate of Incorporation prohibits
a business combination with an interested stockholder without the approval of the holders of 75% of all voting shares and the vote
of a majority of the voting shares held by disinterested stockholders, unless it has been approved by a majority of the disinterested
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Finally, our Bylaws establish procedures, including
advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals. These
provisions of our Certificate of Incorporation and Bylaws could discourage potential acquisition proposals and could delay or prevent
a change in control of the management of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our common stock is listed on the NASDAQ Capital
Market under the symbol &ldquo;TBIO&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Transfer Agent and Registrar </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The transfer agent and registrar for our common
stock is Wells Fargo Shareowner Services. Its address is 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120 and its
telephone number is 1-855-217-6361.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_008"></A><FONT STYLE="text-transform: uppercase"><B>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we
have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the
particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of
any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires
otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a
particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture
Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement
of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities
being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated
by reference from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following summary of material provisions
of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of
the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and
any related free writing prospectuses we authorize for use in connection with a specific offering of debt securities, as well as
the complete indenture that contains the terms of the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The indenture does not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and
in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or
substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions
designed to give holders of any debt securities protection against changes in our operations or financial condition or transactions
involving us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may issue the debt securities issued under
the indenture as &ldquo;discount securities&rdquo;, which means they may be sold at a discount below their stated principal amount.
These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &ldquo;original issue
discount&rdquo;, or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of
the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described
in more detail in any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title of the series of debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any limit upon the aggregate principal amount that may be issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the maturity date or dates;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the form of the debt securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the applicability of any guarantees;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and
the terms of any subordination;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the price (expressed as a percentage of the aggregate principal amount thereof) at which the debt securities will be issued
is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration
of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into
another security or the method by which any such portion shall be determined;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will
begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining
such dates;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our right, if any, to defer payment of interest and the maximum length of any such deferral period;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may,
at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms
of those redemption provisions;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund
or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities
and the currency or currency unit in which the debt securities are payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral
multiple thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security
for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing
of debt securities of that series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities;
the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other
individual securities, and the depositary for such global security or securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions
upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable,
or how it will be calculated and may be adjusted, any mandatory or optional (at our option or at the holders&rsquo; option) conversion
or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which
shall be payable upon declaration of acceleration of the maturity thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others,
the consolidation, merger or sale covenant;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes in the events of default with respect to the securities and any change in the right of the trustee
or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes in the provisions relating to satisfaction and discharge of the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of
the holders of the debt securities issued under the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the currency of payment of the debt securities if other than U.S. dollars and the manner of determining the equivalent amount
in U.S. dollars;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether interest will be payable in cash or additional debt securities at our or the holders&rsquo; option and the terms and
conditions upon which the election may be made;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal
amounts of the debt securities of the series to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any restrictions on transfer, sale or assignment of the debt securities of the series; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions
or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will set forth in the applicable prospectus
supplement the terms on which a series of debt securities may be convertible into or exchangeable for our Common Stock or our other
securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory,
at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our Common Stock
or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Consolidation, Merger or Sale </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our
ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as
an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations
under the indenture or the debt securities, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Events of Default under the Indenture </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect
to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable,
and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by
us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest
for this purpose;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become
due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or
analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt
securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of
principal or premium, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than
a covenant specifically relating to another series of debt securities, and our failure continues for a period of 90 days after
we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder,
from the trustee or holders of at least 25% of the aggregate principal amount of the outstanding debt securities of the applicable
series; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if specified events of bankruptcy, insolvency or reorganization occur.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If an event of default with respect to debt
securities of any series occurs and is continuing, other than certain specified events of bankruptcy, insolvency or reorganization,
the trustee or the holders of at least 25% of the aggregate principal amount of the outstanding debt securities of that series,
by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if
any, and accrued interest, if any, of such series of debt securities immediately due and payable. If certain specified events of
bankruptcy, insolvency or reorganization occur with respect to us, the principal amount and accrued interest, if any, of each issue
of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any
holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">The holders of a majority of the principal amount
of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and
its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we
have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Subject to the terms of the indenture, if an
event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its
rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities,
unless such holders have offered the trustee reasonable indemnity. The holders of a majority of the principal amount of the outstanding
debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that
series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the direction so given by the holder is not in conflict with any law or the applicable indenture; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal
liability or might be unduly prejudicial to the holders not involved in the proceeding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A holder of the debt securities of any series
will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies,
only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the holder has given written notice to the trustee of a continuing event of default with respect to that series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the holders of at least 25% of the aggregate principal amount of the outstanding debt securities of that series have made a
written request,</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred
by the trustee in compliance with the request; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the trustee does not institute the proceeding, and does not receive from the holders of a majority of the aggregate principal
amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request
and offer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These limitations do not apply to a suit instituted
by a holder of debt securities if we default in the payment of the principal of, or the premium, if any, or interest on, the debt
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will periodically file statements with the
trustee regarding our compliance with specified covenants in the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Modification of Indenture; Waiver </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, we and the trustee may change an indenture without the consent
of any holders with respect to specific matters, including, but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to comply with the provisions described above under &ldquo;&mdash;Consolidation, Merger or Sale&rdquo;;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to provide for uncertificated debt securities in addition to or in place of certificated debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions
for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance,
of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right
or power conferred upon us in the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or purposes of
issue, authentication and delivery of debt securities, as set forth in the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material
respect;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to provide for the issuance of, and to establish the form and terms and conditions of, the debt securities of any series as
provided above under &ldquo;&mdash;General Matters&rdquo;, to establish the form of any certifications required to be furnished
pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of
debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture
Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, under the indenture, the rights
of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least
a majority of the aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may
make the following changes only with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>extending the fixed maturity of any debt securities of any series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable
upon the redemption of any series of debt securities; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification
or waiver.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The indenture provides that we can elect to
be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including,
but not limited to, the following obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide for payment;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>register the transfer or exchange of debt securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>replace stolen, lost or mutilated debt securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pay principal of and premium and interest on any debt securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintain paying agencies;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>hold monies for payment in trust;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recover excess money held by the trustee;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>compensate and indemnify the trustee; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>appoint any successor trustee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In order to exercise our rights to be discharged,
we must deposit with the trustee money or government obligations sufficient to pay all the principal of, and any premium, if any,
and interest on, the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Form, Exchange and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will issue the debt securities of each series
only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations
of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary
or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company,
New York, New York, known as DTC, or another depositary named by us and identified in the applicable prospectus supplement with
respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description
of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">At the option of the holder, subject to the
terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the
holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any
authorized denomination and of like tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Subject to the terms of the indenture and the
limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may
present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon
duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer
agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer
or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes
or other governmental charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will name in the applicable prospectus supplement
the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt
securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve
a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each
place of payment for the debt securities of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we elect to redeem the debt securities of
any series, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of
business 15 days before the date of mailing of a notice of redemption of any debt securities that may be selected for redemption
and ending at the close of business on the date of the mailing; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except for the unredeemed
portion of any debt securities we are redeeming in part.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The trustee, other than during the occurrence
and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth
in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent
person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation
to exercise any of the powers given to it by the indenture at the request of any holder of debt securities unless it is offered
reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless we otherwise indicate in the applicable
prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in
whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record
date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will pay principal of and any premium and
interest on the debt securities of a particular series at the office of the paying agents designated by us, except that, unless
we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the
holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate
the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series.
We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities
of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">All money we pay to a paying agent or the trustee
for the payment of the principal of, or any premium or interest on, any debt securities that remains unclaimed at the end of two
years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security
thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The indenture and the debt securities, and any
claim, controversy or dispute arising under or related to the indenture or the debt securities, will be governed by and construed
in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Unsecured Convertible Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the terms of an Unsecured Convertible
Promissory Note Purchase Agreement, or the Note Purchase Agreement, dated December 31, 2014, by and among the Company and certain
accredited investors, the Company issued and sold, in a private placement, unsecured convertible promissory notes, or the Notes,
in the aggregate principal amount of $1,675,000. In accordance with the terms of the Notes, the outstanding principal and unpaid
interest accrued under each Note is convertible into shares of Common Stock as follows: (i) commencing upon the date of issuance
of the Note (but no earlier than January 1, 2015), the investor holding such Note is entitled to convert, on a one-time basis,
up to 50% of the outstanding principal and unpaid interest accrued under the Note, into shares of Common Stock at a conversion
price equal to the lesser of (a) the average closing price of the Common Stock on the principal securities exchange or securities
market on which the Common Stock is then traded, or the Market, for the 20 consecutive trading days immediately preceding the date
of conversion, and (b) $2.20 (subject to adjustment for stock splits, stock dividends, other distributions, recapitalizations and
the like); and (ii) commencing February 15, 2015, the investor holding such Note is entitled to convert, on a one-time basis, any
or all of the remaining outstanding principal and unpaid interest accrued under the Note, into shares of Common Stock at a conversion
price equal to 85% of the average closing price of the Common Stock on the Market for the 15 consecutive trading days immediately
preceding the date of conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the terms of the Note Purchase Agreement,
the Company is obligated to use its best efforts to file with the SEC by January 31, 2016 a registration statement to register
for resale all of the shares of Common Stock issued on or prior to November 30, 2015 pursuant to the conversion of any portion
of the Notes, or the Initial Registration Statement, and to use its commercially reasonable efforts to have the Initial Registration
Statement declared effective by the SEC by March 31, 2016. In addition, the Company is obligated to use its best efforts to file
with the SEC by January 31, 2017 an additional registration statement to register for resale all of the shares of Common Stock
issued pursuant to the conversion of any portion of the Notes that have not previously been registered for resale, or the Additional
Registration Statement, and to use its commercially reasonable efforts to have the Additional Registration Statement declared effective
by the SEC by March 31, 2017. Under the Note Purchase Agreement, the Company may be required to effect one or more other registrations
to register for resale the shares of Common Stock issued or issuable under the Notes in connection with certain &ldquo;piggy-back&rdquo;
registration rights granted to the investors in the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company sold the Notes to &ldquo;accredited
investors&rdquo;, as that term is defined in the Securities Act and in reliance on the exemption from registration afforded by
Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions
of state securities or &ldquo;blue sky&rdquo; laws. Accordingly, the Notes and the shares of Common Stock issued or issuable under
the Notes have not been registered under the Securities Act and such securities may not be offered or sold in the United States
absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Senior Debt </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On March 13, 2013, the Company entered into
a Loan and Security Agreement, or the Loan Agreement, with Third Security, LLC and its affiliates, or the Lenders, for a revolving
line of credit, or the Revolving Line, and a term loan, or the Term Loan. The Loan Agreement, as amended to date, is referred to
herein as the Amended Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Revolving Line</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company may borrow up to $3.0 million under
the Revolving Line. Pursuant to the terms of the Loan Agreement, amounts advanced under the Revolving Line bear interest at an
annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3.0%. The current interest rate is
6.25% under the Amended Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the
Revolving Line. In accordance with the terms of the Amended Loan Agreement, the Company paid the Lenders an upfront fee of $20,000,
and are obligated to pay the Lenders an additional commitment fee of $20,000 on each one-year anniversary of March 13, 2013 during
the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving
Line. The Revolving Line matures on September 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Term Loan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company received $4.0 million under the
Term Loan on March 13, 2013. Interest under the Term Loan accrues at the annual rate of one month LIBOR plus 6.1%, subject to a
LIBOR floor of 3%. The Company was required to make interest-only payments under the Term Loan through December 31, 2013, principal
and interest payments on a monthly basis in each of January and February 2014 using a straight-line amortization rate, and principal
and interest payments on a monthly basis beginning on April 1, 2015 through maturity using a straight-line amortization rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company paid the Lenders an upfront fee
of $40,000 for the Term Loan, and will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the
Term Loan. In addition, if the Company repays the Term Loan prior to maturity, it will pay the Lenders a prepayment penalty of
2.5% of the total outstanding balance under the Term Loan if the prepayment occurs prior to March 13, 2015, and 1.0% of the total
outstanding balance under the Term Loan if the prepayment occurs thereafter. The Term Loan matures on September 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Additional Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Amended Loan Agreement contains affirmative
and negative covenants reasonably customary for similar credit facilities. Under the Term Loan, the Company is required to maintain
a minimum liquidity ratio and achieve a minimum amount of revenue, and the Company also agreed not to (i) pledge or otherwise encumber
its assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase its capital stock,
or (iv) enter into certain mergers or acquisitions without the Lenders&rsquo; consent. Additionally, the Amended Loan Agreement
contains a subjective acceleration clause at the discretion of the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To secure the repayment of any amounts borrowed
under the Revolving Line and the Term Loan, the Company granted the Lenders a security interest in all of the Company&rsquo;s assets.
The occurrence of an event of default under the Amended Loan Agreement could result in the acceleration of the Company&rsquo;s
obligations under the Amended Loan Agreement and would increase the applicable interest rate under the Revolving Line or the Term
Loan (or both) by 5.0%, and permit the Lenders to exercise remedies with respect to the collateral under the Amended Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_009"></A><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following description, together with the
additional information we may include in any applicable prospectus supplements and free writing prospectuses we have authorized
for use in connection with a specific offering, summarizes the material terms and provisions of the warrants that we may offer
under this prospectus, which may consist of warrants to purchase Common Stock, Preferred Stock or debt securities and may be issued
in one or more series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Warrants may be issued independently or together
with Common Stock, Preferred Stock or debt securities offered by any prospectus supplement, and may be attached to or separate
from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this
prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable
prospectus supplement and any applicable free writing prospectus we authorize for use in connection with the specific offering.
The terms of any warrants offered under a prospectus supplement may differ from the terms described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have filed forms of the warrant agreements
as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement
of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant
agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are
offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified
in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular
series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to
the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses we
have authorized for use in connection with a specific offering, and the complete warrant agreements and warrant certificates that
contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will describe in the applicable prospectus
supplement the terms relating to a series of warrants being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title of such securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the offering price or prices and aggregate number of warrants offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the currency or currencies for which the warrants may be purchased;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued
with each such security or each principal amount of such security;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the date on and after which the warrants and the related securities will be separately transferable;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one
warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase Common Stock or Preferred Stock, the number of shares of Common Stock or Preferred Stock,
as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares
may be purchased upon such exercise;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms of any rights to redeem or call the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms of any rights to force the exercise of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the dates on which the right to exercise the warrants will commence and expire;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the manner in which the warrant agreements and warrants may be modified;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a discussion of any material or special United States federal income tax consequences of holding or exercising the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms of the securities issuable upon exercise of the warrants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Before exercising their warrants, holders of
warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or
interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants to purchase Common Stock or Preferred Stock, the right to receive dividends, if any, or, payments upon
our liquidation, dissolution or winding up or to exercise voting rights, if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exercise of Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each warrant will entitle the holder to purchase
the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise
the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the
warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately
available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate
and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant
agent in connection with the exercise of the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Upon receipt of the required payment and the
warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office
indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If
fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate
for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender
securities as all or part of the exercise price for warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless we provide otherwise in the applicable
prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the
warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Enforceability of Rights by Holders of Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each warrant agent will act solely as our agent
under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of
any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will
have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty
or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right
to exercise, and receive the securities purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Outstanding Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of January 31, 2015, warrants to purchase
2,376,059 shares of Common Stock with an average exercise price of $9.24 per share were outstanding, and warrants to purchase 1,293,102
shares of Series A Preferred with an average exercise price of $2.32 per share were outstanding. Except for certain warrants to
purchase 374,618 shares of Common Stock, all of the outstanding warrants are currently exercisable, and all outstanding warrants
contain provisions for the adjustment of the exercise price in the event of stock dividends, stock splits, reorganizations, reclassifications
or mergers. In addition, certain of the warrants contain a &ldquo;cashless exercise&rdquo; feature that allows the holders thereof
to exercise the warrants without a cash payment to us under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="b_010"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may issue units consisting of any combination
of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit
certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent
will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus
supplement relating to a particular series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following description, together with the
additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may
offer under this prospectus. You should read any prospectus supplement and any free writing prospectus we authorize for use in
connection with a specific offering of units, as well as the complete unit agreements that contain the terms of the units. Specific
unit agreements will contain additional important terms and provisions and we will file as an exhibit to the registration statement
of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of
each unit agreement relating to units offered under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we offer any units, certain terms of that
series of units will be described in the applicable prospectus supplement, including, without limitation, the following, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title of the series of units;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>identification and description of the separate constituent securities comprising the units;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price or prices at which the units will be issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date, if any, on and after which the constituent securities comprising the units will be separately transferable;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a discussion of certain U.S. federal income tax considerations applicable to the units; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other terms of the units and their constituent securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_011"></A><B>LEGAL OWNERSHIP OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We can issue securities in registered form or
in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons
who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this
purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the securities. We refer to those
persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &ldquo;indirect
holders&rdquo; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued
in book-entry form or in street name will be indirect holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Book-Entry Holders </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may issue securities in book-entry form only,
as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities
registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that
participate in the depositary&rsquo;s book-entry system. These participating institutions, which are referred to as participants,
in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Only the person in whose name a security is
registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or
its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and
we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants,
which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do
so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of
the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a result, investors in a global security
will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other
financial institution that participates in the depositary&rsquo;s book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Street Name Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may terminate a global security in certain
situations, as described under &ldquo;&mdash;Special Situations When a Global Security Will Be Terminated&rdquo;, or issue securities
that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &ldquo;street
name&rdquo;. Securities held by an investor in street name would be registered in the name of a bank, broker or other financial
institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account
he or she maintains at that institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For securities held in street name, we or any
applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose
names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all
payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial
owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors
who hold securities in street name will be indirect holders, not holders, of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Legal Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our obligations, as well as the obligations
of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not
have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means.
This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing
the securities only in global form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For example, once we make a payment or give
a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal holder is required,
under agreements with its participants or customers or by law, to pass the payment or notice along to the indirect holders but
does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences
of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event,
we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal
holders contact the indirect holders is up to the legal holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Special Considerations for Indirect Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If you hold securities through a bank, broker
or other financial institution, either in book-entry form because the securities are represented by one or more global securities
or in street name, you should check with your own institution to find out:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>how it handles securities payments and notices;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether it imposes fees or charges;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>how it would handle a request for the holders&rsquo; consent, if ever required;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted
in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>how it would exercise rights under the securities if there were a default or other event triggering the need for holders to
act to protect their interests; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the securities are in book-entry form, how the depositary&rsquo;s rules and procedures will affect these matters.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A global security is a security that represents
one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global
securities will have the same terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each security issued in book-entry form will
be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee
that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise
in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary
for all securities issued in book-entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A global security may not be transferred to
or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination
situations arise. We describe those situations below under &ldquo;&mdash;Special Situations When a Global Security Will Be Terminated&rdquo;.
As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities
represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial
interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with
the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will
not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the prospectus supplement for a particular
security indicates that the security will be issued as a global security, then the security will be represented by a global security
at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Special Considerations for Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As an indirect holder, an investor's rights
relating to a global security will be governed by the account rules of the investor's financial institution and of the depositary,
as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and
instead deal only with the depositary that holds the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If securities are issued only as global securities,
an investor should be aware of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for
his or her interest in the securities, except in the special situations described below;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection
of his or her legal rights relating to the securities, as described above;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that
are required by law to own their securities in non-book-entry form;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing
the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the depositary&rsquo;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters
relating to an investor&rsquo;s interest in the global security;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we and any applicable trustee have no responsibility for any aspect of the depositary&rsquo;s actions or for its records of
ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security
within its book-entry system use immediately available funds, and your broker or bank may require you to do the same; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>financial institutions that participate in the depositary&rsquo;s book-entry system, and through which an investor holds its
interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the
securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There may be more than one financial intermediary
in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Special Situations When a Global Security Will Be Terminated
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In a few special situations described below,
a global security will terminate and interests in it will be exchanged for physical certificates representing those interests.
After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors
must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so
that they will be direct holders. The rights of holders and street name investors are described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A global security will terminate when the following
special situations occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global
security and we do not appoint another institution to act as depositary within 90 days;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if we notify any applicable trustee that we wish to terminate that global security; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if an event of default has occurred with regard to securities represented by that global security and has not been cured or
waived.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The applicable prospectus supplement may also
list additional situations for terminating a global security that would apply only to the particular series of securities covered
by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is
responsible for deciding the names of the institutions that will be the initial direct holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_012"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may sell the securities from time to time
pursuant to underwritten public offerings, &ldquo;at the market&rdquo; offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more
purchasers. We may distribute securities from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at a fixed price or prices, which may be changed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at market prices prevailing at the time of sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at prices related to such prevailing market prices; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at negotiated prices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A prospectus supplement or supplements (and
any related free writing prospectus that we may have authorized for use in connection with a specific offering) will describe the
terms of the offering of the securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the name or names of the underwriters, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any over-allotment options under which underwriters may purchase additional securities from us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any agency fees or underwriting discounts and other items constituting agents&rsquo; or underwriters&rsquo; compensation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any public offering price;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any discounts or concessions allowed or re-allowed or paid to dealers; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any securities exchange or market on which the securities may be listed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.9in; text-indent: -0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Only underwriters named in the prospectus supplement
will be underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If underwriters are used in the sale, they will
acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed
public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the
securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to
the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject
to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement,
other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed
or re-allowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship.
We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may sell securities directly or through agents
we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any
commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will
act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may authorize agents or underwriters to solicit
offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future.
We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may provide agents and underwriters with
indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments
that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions
with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">All securities we may offer, other than Common
Stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities,
but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity
of the trading markets for any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any underwriter may engage in over-allotment,
stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Securities Exchange
Act of 1934, as amended, or the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short
position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed
a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either
through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions.
Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer
are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities
to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any underwriters that are qualified market makers
on the NASDAQ Capital Market may engage in passive market making transactions in the common stock on the NASDAQ Capital Market
in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the
commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations
and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess
of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&rsquo;s bid,
however, the passive market maker&rsquo;s bid must then be lowered when certain purchase limits are exceeded. Passive market making
may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if
commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In compliance with guidelines of the Financial
Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent
broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and the applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="b_013"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated in the applicable
prospectus supplement, the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon
for us by Paul Hastings LLP, Palo Alto, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="b_014"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The consolidated financial statements of Transgenomic,
Inc. included in Transgenomic, Inc.&rsquo;s Annual Report (Form 10-K) as of December 31, 2013 and for the year then ended, have
been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report incorporated
herein by reference. Such financial statements are incorporated herein in reliance upon the report of Ernst &amp; Young LLP pertaining
to such financial statements given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The audited consolidated financial statements
of Transgenomic, Inc. and subsidiary as of December 31, 2012 and December 31, 2011 included in our Annual Report on Form 10-K for
the year ended December 31, 2013 incorporated by reference in this prospectus have been audited by McGladrey LLP, independent registered
public accounting firm, as stated in their report dated March 14, 2013, which is incorporated by reference herein, and has been
so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="b_015"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a reporting company and file annual,
quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement
on Form S-3 under the Securities Act with respect to the securities being offered under this prospectus. This prospectus does not
contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further
information with respect to us and the securities being offered under this prospectus, we refer you to the registration statement
and the exhibits and schedules filed as a part of the registration statement. You may read and copy the registration statement,
as well as our reports, proxy statements and other information, at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference
Room. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding
issuers that file electronically with the SEC, including Transgenomic, Inc. The SEC&rsquo;s Internet site can be found at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="b_016"></A>IMPORTANT INFORMATION INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information into this prospectus, which means that we can disclose important information to you by referring you to another document
filed separately with the SEC. The documents incorporated by reference into this prospectus contain important information that
you should read about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following documents are incorporated by
reference into this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 5%">(a)</td>
    <td style="width: 93%">The Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the SEC on March 27, 2014, and Amendment No. 1 to the Annual Report on Form 10-K/A for the fiscal year ended December 31, 2013, filed with the SEC on September 5, 2014;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>(b)</td>
    <td>The Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 24, 2014;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>(c)</td>
    <td>The Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, filed with the SEC on May 15, 2014;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>(d)</td>
    <td>The Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, filed with the SEC on August 8, 2014;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>(e)</td>
    <td>The Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 12, 2014;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>(f)</td>
    <td>The Registrant&rsquo;s Current Reports on Form 8-K filed with the SEC on (i) January 14, 2014, (ii) January 16, 2014, (iii) January 28, 2014, (iv) March 6, 2014, (v) March 19, 2014, (vi) May 6, 2014, (vii) May 14, 2014, (viii) May 15, 2014, (ix) July 2, 2014, as accepted by the SEC at 4:25 p.m. Eastern time, (x) October 22, 2014, (xi) November 5, 2014, (xii) December 23, 2014; (xiii) January 7, 2015; (xiv) January 14, 2015 (but solely as to the matters disclosed under Item 8.01 thereunder and Exhibit 99.2 thereto), and (xv) January 20, 2015; and</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>(g)</td>
    <td>The description of the Registrant&rsquo;s common stock set forth in the Registrant&rsquo;s Registration Statement on Form 8-A (File No. 001-36439), filed with the SEC on May 5, 2014, including any amendments or reports filed for the purpose of updating such description.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also incorporate by reference any future
filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are
related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which
this prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that
indicates the termination of the offering of the securities made by this prospectus and will become a part of this prospectus from
the respective dates that such documents are filed with the SEC. Any statement contained herein or in a document incorporated or
deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof or of the related
prospectus supplement to the extent that a statement contained herein or in any other subsequently filed document which is also
incorporated or deemed to be incorporated herein modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Documents incorporated by reference are available
from us, without charge. You may obtain documents incorporated by reference in this prospectus by requesting them in writing or
by telephone at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Transgenomic, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Attn: Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">12325 Emmet Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Omaha, NE 68164</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Phone: (402) 452-5400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Fax: (402) 452-5461</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">E-mail: investorrelations@transgenomic.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tlogo2.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$3,500,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Craig-Hallum Capital Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>June 7, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tlogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 40$? P$1  (1 0,1 ?_$ +    $#!0$!
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M2-2>L]8T-BAI*%+*0?AWQYN:2:3;]2'QJ$P!_P N"M$@)I$ O8(G:USD3=J
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MFG>B2AWSC6V-G@;N>+#-VZ-K6ZG;MK3[*:D[@BSMI ;C9%>!'"BDX$R3IMN
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M&+QB]S#Z#E4K2GRN_P!:J#R$3E,]=.L?(/)>;<\]S\I^TX-EP8XF4_1.@/\
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M1<<HH=0IMP.5#&1$5%!-_%^(=2!GLHA(0DJV@_ZH@KXAB5**@A,SW?SC8.;
MM]4DBT"VHDZ$RB!)DAV+/V4KVVQFR2;]$ JX2(0W0#!6NHRLODE%,]TD:>;M
MUA]CC6%0Z6;FU;=8<'F41\LM*3K..<@,/V7%1+Z):V/;T7&2#@ZKR(9Q+!NR
M>"F9-1N=XDDHH"ZB2R8&3,)OI"O0-2E9:]W)(6HD#6<,VW'\.MM:KC',I="C
MMG68'RUG2-\SL:*;&D/_ *[$E)-% DX@E'LRH2Q@0(U;F>%$X@HFV;I%*("
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D(-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tlogo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1P#^ P$1  (1 0,1 ?_$ +$   $#!0$!
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MU+@MY;VT:V%SA<@!2 #D,2?&NANK+*MW([.<J:A!%0A]S <JB8E.0I0.F)
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MPN'6>+]_7UN_J!\L]!J\!9^Z(VBB&$121!>36,(>FY@#T -6W).1WNZ6D3'
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M<(6&*C7^0))M!S)&)W;!208J>=TJ5?<"[["("(?'7L%KM=G'8,L675^+ST5
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M7+-F6LY>L=+:5YC,9N3ODW2OS!F[3K5<85((%!])H <&R\J_=)@*H)E.'?\
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MJ480]X+LL#V=W@:\P81GW!3 [$7*6PF '20*G$_>*(K%(!14!,HF!,# (;?
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IOQI6";/[0Q .E]J) *)^Y+Q '0.[?;PA]77TVW^&DXJO6G%:G337_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
